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Members  of  the  Synaptopodin  family  regulate  α-actinin  and  actin-bundling  
activity,  in  an  isoform  specific  manner  (Asunama  et  al.,  2005).  The  ability  to  affect  actin  
polymerization  and  bundling  highlights  the  critical  role  that  synaptopodin  members  play 
in  normal  and  pathologic  cells.  Synaptopodin-2  (Synpo2)  is  one  member  of  the  
synaptopodin  family  that  is  capable  of  inducing  actin  polymerization  (Chalovich  &  
Schroeter,  2010),  suggesting  an  important  role  in  cell  migration,  adhesion,  division,  and  
development.  Synpo2  has  also  been  described  as  a  valuable  biomarker  for  several  
invasive  cancers  due  to  its  ability  to  alter  cell  motility  in  response  to  external  stimuli  (Kai  
et  al,  2015).  Although  most  data  support  the  Synpo2’s  role  as  a  tumor  suppressor  (Xia  
et  al.,  2018;  Liu,  et  al.,  2018;  Kai  et  al,  2012;  Cebrian  et  al.,  2008;  Sanchez-Carbayo  et  
al.,  2003;  Jing  et  al.,  2004;  Lin  et  al.,  2001),  it  has  been  reported  that  under  certain  
conditions,  the  loss  of  Synpo2  expression  led  to  decreased  motility  and  invasiveness 
(De  Ganck  et  al,  2009).  These  contradictory  reports  of  the  influence  of  the  expression  of  
Synpo2  in  cell  migration  and  tumor  stimulation/suppression  demonstrate  the  need  for  
  
further  research.  Synpo2  exists  as  five  isoforms,  which  are  the  result  of  alternative  
splicing  and  cause  differences  at  the  N-terminal  end  of  the  proteins  (Chalovich  &  
Schroeter,  2010).  Each  isoform  has  a  unique  response  to  different  chemokinetic  stimuli  
(Kai  et  al.,  2012).  To  improve  the  understanding  of  individual  roles  that  these  isoforms  
play  in  human  colorectal  cancer  cells,  this  study  considers  the  difference  in  expression  
of  specific  Synpo2  isoforms  in  HT29  cells.  We  observed  intense  and  irregular  staining  in  
areas  within  the  nucleus,  with  a  pattern  that  was  90%  correlated  with  markers  of  
nucleoli.  Furthermore,  transcriptional  inhibition  resulted  in  a  loss  of  nuclear  stain.  
Induction  of  differentiation  in  HT29  cells  with  sodium  butyrate,  resulted  in  a  loss  of  
nuclear  expression  detected  by  the  synaptopodin  2  antibody,  but  showed  an  increase  in  
previously  undetected  cytoplasmic  expression.  RT-PCR  and  Western  blot  analysis  
showed  that  HT29  cells  lacked  Synpo2  isoform  B,  but  expressed  its  smaller  truncated  
isoform,  myopodin.  Nuclear  fractions  detected  the  expression  of  a  smaller  
cross-reactive  protein  at  approximately  55  kDa.  This  unexpected  protein  recognized  by  
our  affinity  purified  antibody  could  potentially  be  a  previously  uncharacterized  Synpo2  
isoform.  The  nucleolar  expression  detected  though  immunofluorescence  suggests  a  
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CHAPTER  1:  INTRODUCTION  
SECTION  1-1:  The  synaptopodin  family  
There  are  three  members  of  the  synaptopodin  family  that  have  been  described:  
synaptopodin,  synaptopodin-2,  and  synaptopodin-2-like.  Synaptopodin,  the  founding  member  of  
the  family,  was  first  discovered  in  kidney  podocytes  and  postsynaptic  densities  of  telencephalic  
synapses  (Mundel  et  al.,  1997).  Synaptopodin-2  (Synpo2),  also  referred  to  as  fesselin  or  
myopodin,  was  discovered  in  avian  smooth  muscle  (Leinweber  et  al.,  1999),  and  later  described  
in  heart  and  skeletal  muscle  and  is  thought  to  be  involved  in  cytoskeletal  organization  (Weins  et  
al.,  2001).  Synaptopodin-2-like,  also  known  as  tritopodin  (Claeys  et  al.,  2009)  or  CHAP  ( Beqqali,  
2010) ,  is  similar  to  synaptopodin-2  in  that  it  is  found  in  the  heart  and  skeletal  muscle  tissue  and  
functions  to  stabilize  sarcomeres.   
Each  of  the  three  family  members  have  their  own  isoforms  that  are  produced  by  
alternative  splicing  (De  Ganck  et  al.,  2008;  Chalovich  and  Schroeter,  2010).  An  important  and  
defining  characteristic  of  the  synaptopodin  family  is  that  each  protein  is  basic  and  has  a  high  
proline  content.  Being  rich  in  proline,  prevents  these  proteins  from  forming  any  secondary  or  
tertiary  structures  under  normal  physiological  conditions  (Khaymina  et  al.,  2007).  Therefore,  
synaptopodin  family  members  are  capable  of  acting  as  a  hub  protein,  interacting  with  other  
proteins.  One  common  characteristic  of  the  synaptopodin  family  members  is  its  ability  to  bind  
actin  and  several  actin  associating  proteins  (Asanuma  et  al.,  2005;  Yu  &  Luo,  2006;  Schroeter  &  
Chalovich,  2004;  Kołakowski  et  al. ,  2004).  This  thesis  focuses  on  synaptopodin-2,  which  has  
been  shown  to  not  only  bind  actin,  but  also  to  stimulate  its  polymerization  and  bundle  actin  
filaments  (Beall  &  Chalovich,  2001).   
  
SECTION  1-2:  Introduction  to  Synaptopodin-2  and  its  isoforms  
Five  different  isoforms  of  Synpo2  have  been  described  as  a  product  of  alternative  
splicing  (Chalovich  &  Schroeter,  2010).  With  the  exception  of  myopodin,  and  the  smallest  
unnamed  isoform,  each  of  the  synaptopodin-2  transcript  variants  includes  exon  1,  2,  3,  and  the  
complete  4a  (Figure  1).  The  mRNA  transcript  variants  1,  2,  and  3  include  either  exons  6,  4b  or  5  
and  encodes  a  1261,  1093  or  1109  amino  acids  long  protein,  respectively  known  as  isoform  A,  
isoform  B,  and  isoform  C  (Chalovich  &  Schroeter,  2010).  The  smallest  synaptopodin-2  isoform  is  
unnamed  and  only  includes  exons  1,  2  and  a  small  portion  of  exon  6.  Myopodin  is  the  smallest  
named  synaptopodin-2  isoforms,  which  is  698  amino  acids  long  and  only  includes  689  of  the  
794  amino  acids  of  exon  4a  and  all  nine  of  the  amino  acids  of  exon  4b  (Chalovich  &  Schroeter,  
2010).  In  addition  to  the  PDZ  domain  which  is  located  at  the  N-terminal  of  the  longer  isoforms,  
the  nine  amino  acids  that  form  the  4b  exon  are  present  in  isoform  B  and  myopodin,  are  located  
at  the  C-terminal  end  of  these  variants  and  have  been  shown  to  contribute  to  Synpo2’s  ability  to 
respond  to  chemokinetic  stimuli  in  certain  prostate  cancer  cells  (Kai  et  al.,  2012).  
Several  previous  studies  regarding  synaptopodin-2  have  used  the  name  myopodin  to  
describe  all  isoforms  of  synaptopodin-2  (De  Ganck  et  al.,  2008;  Weins  et  al.,  2001;  Kai  et  al.,  
2012;  Lin  et  al.,  2001;  Cebrian  et  al.,  2008).  In  the  literature  review,  we  will  conserve  their  
nomenclature;  however,  to  avoid  confusion,  in  this  thesis  we  will  refer  to  myopodin  as  the  
shortest  named  isoform  as  described  by  Schroeter  and  Chalovich  (2010).   The  other  isoforms  




Figure  1:  Synaptopodin-2  Isoforms  
 
















Mammalian  myopodin  was  first  characterized  as  a  novel  actin-bundling  protein  (Weins  et  
al.,  2001)  and  later  shown  to  be  a  product  of  alternative  splicing  of  synaptopodin-2  (Schroeter  et  
al.,  2008).  Previously  to  this,  it  had  been  shown  that  partial  or  complete  deletions  of  myopodin  
and  its  epigenetic  silencing  through  hypermethylation  correlated  to  the  invasiveness  of  prostate 
and  bladder  cancers,  respectively  (Lin  et  al.,  2001;  Cebrian  et  al.,  2008).  The  primers  used  in  
these  studies  were  non-isoforms  specific  (annealing  in  the  region  between  exon  1  and  4a),  and  
therefore,  were  not  amplifying  myopodin  but  instead  all  the  synaptopodin-2  splice  variants.  
Nevertheless,  down-regulating  the  expression  of  synaptopodin-2  has  been  associated  with  
increased  invasiveness  and  motility  in  human  prostate  (PC-3),  bladder  (RT4),  and  breast  
(MDA-MB-231,  BT-549,  SK-BR-3,  MDA-MB-468,  BT-474,  T-47D,  MCF-7,  MDA-MB-453,  
MDA-MB-436,  and  MCF10A)  cancer  cell  lines  (De  Ganck  et  al.,  2008;   Cebrian  et  al.,  2008;  Xia  
et  al.,  2018).  From  these  studies,  the  authors  hypothesized  that  in  normal  cells,  myopodin  
(Synpo2)  acts  as  a  tumor  suppressor  gene  and  its  function  is  correlated  with  its  nuclear  location.  
Further  studies  that  analyzed  the  localization  of  myopodin  in  normal  urothelium  and  bladder  
cancer,  demonstrated  that  in  the  transformed  tissue,  Synpo2  translocates  to  the  cytoplasm,  
where  its  association  with  the  actin  cytoskeleton  is  believed  to  play  a  role  as  a  tumor  promoter  
(De  Ganck  et  al.,  2009).   
Previous  studies  have  also  shown  that  myopodin  is  localized  in  the  nucleus  of  
undifferentiated  C2C12  cells,  but  upon  differentiation  translocates  into  the  cytoplasm  (Weins  et  
al.,  2001)  which  is  in  contradiction  with  its  suggested  tumor  promoter  role  when  expressed  in  
the  cytoplasm.  Over-expression  of  a  wild-type  myopodin,  in  non-invasive  mouse  C2C12  
myoblast  cells  promote  invasion  of  these  cells  into  a  collagen  matrix,  while  over-expression  of  
truncated  myopodin,  which  lack  a  nuclear  export  signal,  do  not  induce  invasiveness  ( Van  Impe  
et  al.,  2003 ).  These  data  demonstrate  that  the  translocation  of  myopodin  between  the  nuclear  




demonstrate  that  more  studies  are  needed  in  order  to  understand  the  role  of  synaptopodin-2  in  
normal  and  transformed  cells.  It  is  important  to  indicate  that  the  above  studies  did  not  
investigate  the  roles  of  individual  isoforms  of  Synpo2.  A  possible  explanation  for  the  contrasting  
results  obtained  could  be  that  the  various  isoforms  may  be  differentially  expressed  in  normal  













Figure  2:  Synaptopodin-2  Localization  in  Normal  and  Cancerous  cells  
  
Figure  2:  Diagram  of  Synaptopodin-2  (myopodin)  localization  and  suggested  function  in  normal  














SECTION  1-3:  Binding  Partners  of  Synaptopodin-2 
Each  member  of  the  synaptopodin  family  (synaptopodin,  synaptopodin-2,  and  
synaptopodin  2-like)  are  proline  rich  basic  proteins,  preventing  the  formation  of  globular  
domains  (Mundel  et  al,  1997).  Synaptopodin-2  has  also  been  shown  to  act  as  a  hub  protein  
(Khaymina  et  al.,  2007);  allowing  it  to  bind  to  multiple  binding  partners.  Hub  proteins  have  
received  a  significant  amount  of  attention  in  recent  years  because  of  their  capability  to  form  
numerous  physical  interactions;  their  role  is  essential  in  mediating  several  cellular  processes,  
which  could  serve  as  a  potential  therapeutic  value.  
Fesselin  was  described  by  Schroeter  et  al.  as  the  avian  homolog  of  mammalian  
synaptopodin-2  (2008).  Fesselin  is  an  actin  binding  protein  (Leinweber  et  al.,  1999)  that  
stimulates  actin  nucleation  and  polymerization.  Synaptopodin-2  binds  both  F  and  G-actin,  and  
causes  rapid  polymerization  of  G-actin  into  F-actin,  when  compared  to  unbound  G-actin  (Beall  &  
Chalovich,  2001).  The  formation  of  nucleation  centers  occurs  at  a  ratio  of  3  actin  monomers  to  1  
synaptopodin-2  protein  (Figure  3).  Schroeter  and  Chalovich  found  nucleation  center  formation  is  
regulated  by  the  concentration  of  calcium-calmodulin  (2004).  Although  in  the  presence  of  
calcium-calmodulin,  the  binding  of  fesselin  to  F-actin  and  its  ability  to  bundle  F-actin  is  
unaffected,  fesselin’s  stimulatory  effect  on  G-actin  polymerization  was  significantly  reduced,  
suggesting  that  fesselin  has  a  major  role  as  an  actin-polymerizing  factor  (Schroeter  and  
Chalovich,  2004).  
The  assembly  of  G-actin  into  F-actin  is  a  major  contributing  factor  to  the  cell  
cytoskeleton  architecture  and  as  such  plays  a  crucial  role  in  many  cell  functions  from  movement  
and  organelle  distribution  to  the  regulation  of  gene  expression.  Actin  filaments  are  extremely  
dynamic  structures  whose  state  of  assembly  is  largely  dependent  on  actin-binding  proteins  
(ABPs).  Since  actin  polymerization  rates  have  such  a  crucial  role  in  the  reorganization  of  the  cell  




responsible  for  mediating  these  processes  (Lodish  et  al.,  2000).  These  data  suggest  that  
Synpo2  may  regulate  important  cellular  functions,  such  as  cell  cycle  progression  and  cell  
motility.  Aside  from  actin,  several  additional  proteins,  such  as  myosin,  calmodulin,  α-actinin  and  
zyxin  have  been  shown  to  associate  with  synaptopodin-2  (Asanuma  et  al.,  2005;  Pham  &  
Chalovich,  2006;  Yu  &  Luo,  2006;  Shen  et  al.,  2005).  Multiple  interactions  are  thought  to  be  
possible  because  Synpo2  lacks  any  real  secondary  and  tertiary  structures  in  its  native  state  
(Khaymina  et  al.,  2007).  Synaptopodin-2  has  been  shown  to  co-localize  with  α-actinin  
(Linnemann  et  al.,  2010).  Previous  research  suggests  that  members  of  the  synaptopodin  family  
associate  with  specific  α-actinin  isoforms  to  promote  the  polymerization  of  actin  (Asanuma  et  
al.,  2005).  Association  with  α-actinin-4,  an  isoform  of  α-actinin  that  has  been  shown  to  shuttle  
from  the  cytoplasm  to  the  nucleus  during  actin  depolymerization  (Honda  et  al.,  1998),  has  been  
linked  with  the  translocation  of  synaptopodin-2  from  the  cytoplasm  to  the  nucleus,  where  it  
induces  actin  bundling  (Weins  et  al.,  2001).  Association  with  cell  cytoskeleton  proteins  suggest  
Synpo2  might  be  involved  with  the  chromatin-remodeling  complex,  and  therefore,  may  be  an  




Figure  3:  Synaptopodin-2  stimulates  actin  polymerization  
  
Figure  3:  Schematic  representation  of  the  proposed  effect  synaptopodin-2  has  on  actin  
polymerization.  Actin  (green)  binds  to  synaptopodin-2  (orange)  to  form  a  complex  at  a  3:1  ratio  











SECTION  1-4:  Cell  Cycle  
The  integrity  of  the  cell’s  genetic  material  is  dependent  on  the  ability  of  the  cell  to  
monitor  DNA  replication  processes  until  completion  or  block  the  transition  of  one  phase  of  the  
cell  cycle  to  the  next  if  any  problem  is  detected  (Cooper,  2000).  There  are  four  distinct  phases  of  
the  cell  cycle:  the  G1  phase,  S  phase,  and  G2  phase,  which  are  collectively  known  as  
interphase  and  the  M  phase  (Figure  4).  During  the  G1  phase,  cells  increase  in  size  and  prepare  
for  DNA  synthesis  which  begins  when  cells  enter  the  S  phase.  The  gap  between  DNA  synthesis  
and  mitosis  is  known  as  G2.  During  G2  the  cells  will  continue  to  grow  until  they  are  ready  to  
undergo  mitosis  (M  phase).  When  cells  reach  M  phase,  cell  growth  will  arrest  and  the  cell  
divides  into  two  daughter  cells  (Cooper,  2000).  The  transitions  between  the  phases  of  the  cell  
cycle  are  unidirectional  and  highly  coordinated.  Checkpoints  in  the  cell  cycle,  working  through  
signal  transduction  pathways,  regulate  the  cell  cycle  in  response  to  cell  stress  or  other  factors.  
For  example,  DNA-damage  will  generate  a  signal  causing  cells  to  arrest  in  the  G1  and  G2  
phases  and  will  slow  down  DNA  synthesis  while  transcription  of  repair  genes  is  induced  
(Johnson  and  Rao,  1970).   
The  progression  through  the  cell  cycle  is  a  highly  ordered  series  of  events  that  is  
critically  dependent  on  several  key  regulatory  proteins.  Countless  proteins  within  the  cell  
undergo  translocation,  some  type  of  modification,  or  vary  in  concentration  in  a  cell-cycle  
dependent  manner.  It  has  been  estimated  that  approximately  700  genes  display  transcriptional  
fluctuation  that  is  consistent  with  cell-cycle  progression  (Cho  et  al.  2001).  A  wide  variety  of  
cytoskeletal  reorganization  genes  are  regulated  in  a  cell-cycle  dependent  manner.  Several  
genes  that  are  involved  in  cell  motility  and  the  extracellular  matrix  are  predominantly  expressed  
in  the  M  phase.  Transcripts  that  are  upregulated  during  S  phase  overlap  with  genes  that  are  




constantly  checking  for  and  repairing  damage  to  the  newly  synthesized  DNA  (Cho  et  al.,  2001).  
Proliferating  cells  are  continuously  repeating  the  cell-cycle  and  are  in  a  constant  protein  flux  to  
meet  the  demands  of  the  cell.  Actively  growing  cells  have  a  high  demand  for  ribosomes,  and  as  
such,  rely  on  the  nucleolus  to  keep  a  steady  supply,  which  will  need  to  be  synthesized  each  time  









Figure  4:  Normal  Cell  Cycle  Progression  
  















SECTION  1-5:  The  Nucleolus  
The  nucleolus  is  the  most  prominent  substructure  located  within  the  nucleus  of  the  cell. 
The  function  of  the  nucleolus  is  intimately  connected  to  cell  growth,  division,  and  proliferation.  
From  the  time  the  nucleolus  was  first  described  until  recent  years,  the  function  of  nucleoli  has  
been  predominately  and  almost  exclusively  associated  with  biogenesis  of  rRNA  by  RNA  
polymerase  I  (Busch  &  Smetana,  1970;  Hadjiolov,  1985).  Due  to  the  elevated  demand  for  
protein  synthesis  in  proliferating  cells,  it  is  estimated  that  rRNA  synthesis  accounts  for  
approximately  50%  of  the  total  RNA  production  in  an  actively  growing  and  dividing  cell  (Zylber  &  
Penman,  1971).   
The  nucleolus  is  not  bound  by  a  membrane,  but  is  organized  around  chromosomal  
regions,  whose  primary  transcript  of  the  rRNA  genes  is  the  large  45S  pre-rRNA,  which  contains  
the  5.8S,  the  18S,  and  the  28S  rRNAs.  There  are  three  distinguishable  regions  within  the  
nucleolus:  the  fibrillar  center,  the  dense  fibrillar  component,  and  the  granular  component  
(Cooper,  2000).  Each  of  the  different  regions  have  a  specific  role  in  rRNA  gene  transcription,  
processing,  and  the  assembly  of  the  ribosome,  within  the  nucleoli.  Transcription  for  the  18S,  
5.8S  and  28S  rRNAs  is  driven  by  nucleolar  RNA  polymerase  I  and  is  located  in  the  fibrillar  
centers,  just  at  the  boundary  with  the  dense  fibrillar  component  of  the  nucleoli  (Cooper,  2000).  
The  pre-rRNA  is  then  processed  in  the  dense  fibrillar  component  and  will  continue  to  be  
processed  in  the  granular  component.  The  5S  rRNA  is  the  fourth  ribosomal  RNA,  which  is  
independently  transcribed  as  a  precursor  by  RNA  polymerase  III,  will  assemble  with  the  5.8S  
and  28S  RNAs  to  form  the  large  60S  (Raska  et  al.,  2004).  Ribosomes  are  assembled  in  the  
granular  component  with  ribosomal  proteins  to  form  pre-ribosomal  subunits,  ready  to  be  
exported  into  the  cytoplasm.  
Although  rRNA  has  largely  been  the  focus  of  nucleolar  activity  for  many  years,  advances  




the  structure  and  composition  of  the  nucleolus,  giving  a  broader  understanding  of  its  role  within  
the  cell.  Today,  the  nucleolus  is  considered  to  be  as  diverse  as  the  proteins  that  it  is  composed  
of.  There  are  over  700  human  proteins  that  have  been  identified  as  nucleolar  and  only  an  
estimated  30%  of  them  play  a  role  in  the  biogenesis  of  ribosomes  (Cho  et  al.  2001).   
  Aside  from  rRNA  transcription,  the  highly  organized  nucleolus  has  a  role  in  cellular  
functions  affecting  cell-cycle  progression,  stress  responses,  and  has  even  been  correlated  to  
ageing  (Tsai  &  McKay,  2002;  Rubbi  &  Milner,  2003;  Raska  et  al.,  2006;  Boulon  et  al.,  2010).  The  
distribution  of  the  nucleolus  has  been  shown  through  previous  studies  to  mediate  the  
stabilization  of  p53  proteins  in  response  to  DNA  damage  and  other  stresses  to  the  cell  (Boulon  
et  al.,  2010).   
Though  the  nucleolus  has  been  studied  in  great  detail,  there  are  still  a  significantly  large  
number  of  uncharacterized/novel  proteins  that  are  yet  to  be  described  for  their  role  within  the  
nucleolus.  Some  of  the  most  intriguing  features  of  the  nucleolus  today  are  correlated  to  their  
expression  in  cancerous  cells.  It  is  understandable  that  cells  that  are  continuously  proliferating,  
such  as  cancerous  cells,  have  a  greater  protein  requirement  than  non-proliferating  cells;  
therefore,  the  up-regulation  in  rRNA  transcription  often  coincides  with  an  increased  size  and/or  
number  of  nucleoli  within  the  cell  (Raska  et  al.,  2006).  Consequently,  the  nucleolus  can  be  used  
as  an  important  biomarker  for  cancer  diagnosis  and  prognosis.  
The  architecture  of  the  nucleolus,  as  with  the  rest  of  the  nucleus,  is  extremely  dynamic  
and  dependent  on  the  physiological  state  of  the  cell.  At  the  end  of  G2,  as  the  cells  enter  mitosis  
the  nuclear  envelope  begins  to  deteriorate  and  most  of  transcriptional  activity  ceases  and  the  
nucleolus  is  broken  down  and  is  then  reassembled  at  the  beginning  of  G1  at  the  onset  of  rRNA  
transcription  (Cooper,  2000).  The  disassembly  and  reassembly  of  the  nuclear  envelope  during  
the  different  phases  of  the  cell  cycle  is  correlated  to  a  continuous  flux,  in  activity  and  location,  of  




Fluctuation  in  several  nucleolar  components  is  correlated  with  transcription  levels.  As  
transcription  is  inhibited,  the  relative  levels  of  nucleolar  components  often  increases  or  
decreases  in  quantity  and  rarely  remains  constant  (Anderson,  2005).  If  the  quantity  of  nucleolar  
components  is  unaffected  by  altered  transcription  levels,  frequently  their  subcellular  localization  
will  be  affected.  Understanding  nucleolar  protein  expression  patterns  can  be  another  useful  tool  
in  identifying  cancer  progression.   
SECTION  1-6:  Colorectal  Cancer  
In  the  United  States,  cancer  is  the  second  leading  cause  of  death  ( Siegel  et  al .,  2020).  
Despite  an  overall  decline  in  cancer  related  deaths  over  the  past  30  years,  colorectal  cancer  is  
still  the  second  leading  cause  of  cancer  death  in  the  United  States  for  men  and  women  ( Siegel   
et  al .,  2020).  Two  factors  have  been  shown  to  dramatically  increase  the  risk  of  developing  
colorectal  cancers;  family  history  and  age  ( Siegel  et  al .,  2020).   
Colorectal  cancer  normally  progresses  through  a  series  of  stages,  Stages  I-IV.   During  
Stage  0,  abnormal  cells  are  formed  in  the  mucosa  of  the  colon.  In  Stage  1,  the  cells  in  the  
mucosa  can  be  either  cancerous  or  precancerous  and  begin  to  spread  to  the  submucosa  and  
the  lower  tissue  layers.  At  Stage  IIA,  the  cancer  has  spread  through  the  muscle  and  reached  the  
serosa.  When  cells  reach  Stage  IIB,  the  cancer  has  breached  the  serosa,  but  has  not  yet  
metastasized  to  other  organs.  Upon  reaching  Stage  IIC  the  cancer  spreads  to  other  nearby  
organs.  Classifying  Stage  III  cancer  is  dependent  upon  the  extent  of  invasion  from  the  origin  
and  by  the  number  of  lymph  nodes  the  cancer  has  spread  to.  At  Stage  IV,  the  cancer  has  
metastasized  to  major  organs  that  are  not  locally  near  the  abdominal  wall  or  colon  (American  
Cancer  Society,  2020).  The  progression  through  these  stages  results  in  the  alteration  of  gene  
expression,  such  as  activating  oncogenes  or  inactivating  tumor  suppressor  genes  ( Bevan  &  




and  colorectal  cancer  cells  will  contribute  to  understanding  the  role  that  Synpo2  has  on  the  
invasiveness  of  colon  cancer  cells.  
A  colorectal  adenocarcinoma  cell  line,  HT29  (ATCC  No.  HTB-38)  was  used  as  the  model  
for  this  study.  During  normal  cell  culture,  HT29  cells  remained  in  an  undifferentiated  state.  
Changing  the  chemical  composition  of  the  growth  media  used  can  induce  differentiation,  
allowing  researchers  to  compare  proliferating  cells  to  non-proliferating  cells.  Upon  differentiation  
the  HT29  cells  form  tight  junctions,  creating  a  monolayer  of  cells  that  also  form  a  brush  border  
membrane.   
SECTION  1-7:  Outline  of  the  project  
The  aim  of  the  present  thesis  is  to  analyze  isoform  specific  (isoform  B  and  myopodin)  
changes  in  expression  upon  differentiation,  using  a  colon  cancer  cell  line  as  a  model.  Isoform  B  
and  myopodin  differ  only  at  the  N-terminal  end.  Knowing  that  Synpo2  is  often  classified  as  a  
tumor  suppressor,  the  effects  of  over-expressing  either  isoform  B  or  myopodin  should  negatively  
affect  the  rate  of  proliferation  and  cell  migration.   
The  first  objective  of  the  study  was  to  determine  which  of  the  Synpo2  isoforms  are  
expressed  in  HT29  cells  at  an  mRNA  and  protein  level,  in  a  differentiated  and  undifferentiated  
state.  RT-PCR  was  performed  to  determine  the  expression  of  isoform  A,  B  and  C  at  an  mRNA  
level  in  a  differentiated  and  undifferentiated  state.  Due  to  the  similarity  between  isoform  B  and  
myopodin,  long-range  PCR  and  Western  blot  analysis  had  to  be  performed  to  determine  if  there  
was  a  difference  in  expression  between  the  two  isoforms.  Myopodin,  not  isoform  B,  was  found  
to  be  expressed  both  at  an  mRNA  and  protein  level.  Similar  in  composition,  but  different  in  
expression,  these  isoforms  were  the  main  focus  for  this  thesis.  To  better  understand  the  function  




overexpression  analysis.  In  parallel  to  overexpression,  knocking  down  the  expression  of  Synpo2  
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Synaptopodin-2  has  been  described  as  a  hub  protein  that  associates  with  cytoskeletal  
proteins,  such  as  actin  and  other  actin  associating  proteins.  In  bladder  and  prostate  cancer  (Lin 
et  al.,  2001;  Sanchez-Carbayo  et  al.,  2003;  Jing  et  al.,  2004;  Yu  et  al.,  2006;  Cebrian  et  al.,  
2008;  De  Ganck  et  al.,  2009),  synaptopodin-2  has  been  suggested  to  act  as  a  tumor  suppressor  
gene  and  its  loss  of  expression  by  deletion  or  hypermethylation  leads  to  an  increased  rate  of  
invasiveness.  More  recent  studies  have  shown  that  the  role  of  synaptopodin-2  is  more  complex  
and  may  be  dependent  on  the  diverse  signals  found  in  the  tumor  microenvironment  (Kai  et  al.,  
2012).  Studies  on  synaptopodin-2  function  are  also  complicated  and  manifold  due  to  the  
presence  of  multiple  isoforms.  At  least  5  synaptopodin-2  isoforms  have  been  described.  Two  of  
these  isoforms,  myopodin  and  isoform  B  possess  the  same  full-length  C-terminal  exon.  This  
project  analyzes  the  localization  and  expression  of  both  these  isoforms  in  HT29  colon  
adenocarcinoma  cells  using  immunofluorescence,  RT-PCR,  and  Western  blot  analysis.  Our  
results  demonstrate  that  myopodin  but  not  synaptopodin-2  isoform  B  is  expressed  in  HT29  cells.  
We  also  identified  a  potentially  new  synaptopodin-2  isoform,  which  is  predominantly  expressed  
in  the  nucleoli  of  undifferentiated  HT29  cells.  Furthermore,  this  nucleolar  expression  is  altered  











Synaptopodin-2  is  a  member  of  the  synaptopodin  family  and  has  been  shown  to  bind  to  
and  promote  actin  polymerization  (Leinweber  et  al.,  1999;  Beall  &  Chalovich,  2001);  it  also  
associates  with  several  other  cytoskeletal  proteins  (Asanuma  et  al.,  2005;  Pham  &  Chalovich,  
2006;  Yu  &  Luo,  2006;  Shen  et  al.,  2005).  Synaptopodin-2  possesses  3  α-actinin  binding  sites  
and  has  been  shown  to  colocalize  with  α-actinin  and  filamin  during  muscle  development  
(Renegar  et  al.,  2009;  Linnemann  et  al.,  2010).  One  α-actinin  isoform,  α-actinin-4,  has  been  
shown  to  shuttle  from  the  cytoplasm  to  the  nucleus  depending  on  the  cell  cycle  phase  (Kumeta  
et  al.,  2010).  Similarly,  Synpo2  expression  has  been  shown  to  translocate  from  the  cytoplasm  to  
the  nucleus  (Weins  et  al.,  2001),  suggesting  a  possible  link  between  Synpo2  and  α-actinin-4.  
The  role  that  Synpo2  plays  within  the  nucleus  is  unclear  and  previous  studies  present  
contradicting  results.  Some  groups  have  suggested  a  tumor  suppressor  role  for  Synpo2  (De  
Gank  et  al.,  2009;  Lin  et  al.,  2001;  Cebrain,  2008),  while  others  have  demonstrated  that  Synpo2  
may  act  as  a  tumor  activator  and  increase  invasiveness  in  prostate  cancer  cells  and  mouse  
myoblast  cells  (DeGanck  et  al.,  2009;  Van  Impe  et  al.,  2003).   
Five  isoforms  of  Synpo2  have  been  characterized  as  the  product  of  alternative  splicing  
(Chalovich  &  Schroeter,  2010).  These  isoforms  mainly  differ  by  their  C  terminus  (isoform  A,  B  
and  C)  and  myopodin  is  a  truncated  version  of  isoform  B,  which  lacks  the  N-terminus  and  is  
encoded  by  exon  1,  2,  3,  and  part  of  4a.  The  smallest  of  the  synaptopodin-2  isoforms  is  
composed  of  exons  1,  2  and  only  a  small  portion  of  exon  6.  It  is  likely  that  these  isoforms  play  
different  roles  and/or  are  expressed  in  different  compartments  of  the  cell.  Most  of  the  studies  in  
this  introduction  did  not  consider  that  different  cell  types  may  express  different  Synpo2  isoforms  
or  that  different  isoforms  may  be  expressed  in  different  cellular  compartments.  To  better  
understand  the  functions  associated  with  Synpo2,  it  is  necessary  to  analyze  individual  isoforms.   
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In  this  study,  we  analyzed  the  expression  pattern  of  myopodin,  a  specific  Synpo2  
isoform,  in  HT29  cells.  Using  RT-PCR,  Western  blot  analysis,  and  immunocytochemistry  with  an 
isoform  specific  antibody  against  the  C-terminus  (exon  4b),  we  showed  the  localization  of  this  
isoform  to  better  understand  some  of  its  possible  roles  in  cancer  cells.  We  showed  that  in  
proliferating  HT29  cells,  myopodin  is  mainly  expressed  in  the  nuclei  with  the  strongest  
expression  being  observed  in  the  nucleoli.  Western  blot  analysis  shows  the  presence  of  a  
possible  new  isoform  of  approximately  55  kDa.   Interestingly  this  new  isoform  is  found  mainly  in  
the  nucleolus  of  HT29  cells.  The  nucleolar  expression  in  proliferating  cells  may  suggest  a  role  in  
transcription  activity.  Upon  cell  differentiation,  when  cells  are  no  longer  proliferating  and  
transcriptional  activity  is  only  at  a  basal  level,  expression  is  translocated  from  the  nucleoli  to  the  
cytoplasm.   
MATERIALS  AND  METHODS  
Cell  culture.  HT29  cells  (ATCC:  HTB-38)  were  grown  in  DMEM/F12  (Gibco-BRL  Life  
Technologies,  Grand  Island,  NY,  USA),  supplemented  with  10%  fetal  bovine  serum,  100  µg/mL  
streptomycin  and  100  IU/mL  penicillin  and  maintained  at  37ᴼC  in  a  humidified  5%  CO 2   
incubator.  Differentiation  was  induced  by  supplementing  normal  media  with  5mM  sodium  
butyrate,  as  previously  described  (Augeron  and  Laboisse,  1984).  
Antibodies.  The  NC_781  is  a  polyclonal  antibody  generated  by  immunization  of  a  rabbit  with  a  
keyhole  limpet  hemocyanin-conjugated  peptide.  The  antibody  was  affinity  purified  against  the  
synaptopodin-2  4b  exon  peptide  sequence:  VWKPSVVEE.  
Immunocytochemistry.  HT29  cells  were  seeded  on  18  mm 2   glass  coverslips  and  allowed  to  
adhere  overnight  under  normal  culturing  conditions.  Each  of  the  following  steps  were  carried  out  
at  room  temperature.  Cells  were  washed  with  1X  PBS  and  fixed  in  3.7  %  formaldehyde  in  1X  
PBS  for  8  minutes.  Cells  were  washed  in  1X  PBS,  permeated  with  0.1  %  Triton-X100  in  1X  PBS  
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for  4  minutes,  and  blocked  in  10  %  FBS  in  1X  PBS  for  45  minutes.  The  primary  NC_781  
antibody  was  diluted  1:600  with  10  %  FBS  in  1X  PBS  and   incubated  with  the  cells  for  45  
minutes.  The  cells  were  then  washed  in  1X  PBS  and  the  secondary  antibody  (Sigma  F1262),  
diluted  1:150,  was  incubated  with  the  cells  for  45  minutes.  The  specificity  of  the  antibody  was  
verified  by  preabsorption  with  the  corresponding  exon  4b  peptide  sequence  that  had  been  used  
for  immunization.  Cell  samples  were  visualized  using  an  Olympus  BX40  microscope,  equipped  
with  a  QColor  5  Olympus  camera  and  the  Qcapture  Pro  6.0  program  and  the  Olympus  Confocal 
Microscope.   
Long-range  PCR.  Primers  were  designed  to  amplify  full-length  isoform  B  and  myopodin  genes,  
using  the  Expand  Long  Template  PCR  System  (Roche).  The  forward  primers  designed  for  
isoform  B  and  myopodin  were:  5’GAG  AAGCTTAAAACATGGGCACAGGGGATTTTATCTGC  3’  
and  5’GAGAAGCTTAAAACATGTTTAAGAAGCGACGTCGGAGG  3’,  respectively.  A  common  
reverse  primer  was  used:  5’GAGGGATCCTT  
AGTGATGGTGATGGTGATGGCCCCCTCCCTCTTCCACAACAGATGGTTTCC3’.  The  optimal  
annealing  temperature  determined  for  the  primer  sets  was  60ᴼC.   
Western  blot.  Cells  were  lysed  in  an  ice-cold  lysis  buffer  (20mM  Tris-HCl  pH  7.5,  137  mM  NaCl,  
2  mM  EDTA  pH  8,  1  %  NP-40,  10  %  Glycerol).  The  lysis  buffer  was  supplemented  with  Pierce  
Protease  Inhibitor  Cocktail  (Thermo  Fisher  Scientific,  88661)  prior  to  use.   Lysates  were  
incubated  for  30  minutes  at  4ᴼC  under  constant  agitation.  Protein  concentrations  were  
determined  through  the  Pierce  assay  using  bovine  serum  albumin  as  a  standard.  Western  
blotting  was  performed  as  described  (Towbin,  1979)  with  the  NC_781  antibody.  Proteins  were  
visualized  by  Immobilon  Western  Chemiluminescent  HRP  Substrate  (Millipore,  WBKLS0100)  
and  visualized  using  the  Chemidoc  XRS  System.   
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Statistics.  Three  hundred  random  cells  were  analyzed  and  the  number  of  instances  when  
NC_781  expression  was  colocalized  with  nucleolin  was  determined.  This  percentage  was  
compared  to  the  number  of  times  NC_781  was  expressed  and  did  not  colocalize  with  nucleolin  
or  when  nucleolin  was  expressed  without  colocalizing  with  NC_781.  Statistical  significance  was  
determined  by  a  two-tailed  t-test  (p  <0.05).  
RESULTS  
RT-PCR  analysis  shows  that  myopodin  not  synaptopodin-2  isoform  B  is  expressed  in  HT29  cells  
In  order  to  determine  which  spliced  variants  of  Synpo2  mRNA  were  expressed  in  HT29  
cells,  we  designed  a  set  of  primers  to  amplify  target  variants  using  long  range  RT-PCR.  Two  
forward  primers  were  designed  to  anneal  to  the  start  ORF  of  isoform  B   (Synpo2StartF)  or  of  
myopodin  (MyopodinForward)  and  a  reverse  primer  that  anneals  to  the  end  of  exon  4b  (Figure  
5A).   Human  skeletal  muscle  cDNA  was  used  as  a  positive  control  to  validate  each  primer  set  
(Figure  5B;  Lanes  2  and  4).  While  we  were  able  to  amplify  the  myopodin  splice  variants  from  
HT29  cells  cDNA,  we  were  not  able  to  amplify  Synpo2  isoform  B  (Figure  5B;  Lane  3).  These  
data  suggest  that  myopodin,  but  not  isoform  B,  is  expressed  in  HT29  cells.  These  data  were  
confirmed  by  Western  blot  analysis  using  whole  cell  lysates.  The  polyclonal  affinity  purified  
antibody  used,  NC_781,  was  designed  to  recognize  an  epitope  encoded  by  exon  4b  and  was  
therefore  recognizing  specifically  either  isoform  B  or  myopodin.  Western  blot  analysis  showed  
the  presence  of  a  75  kDa  protein  (Figure  5C),  which  corresponds  to  the  size  of  myopodin  and  
we  did  not  observe  any  higher  molecular  weight  proteins.  This  data  supports  that  HT29  cells  
express  myopodin,  not  isoform  B.  
  Interestingly,  we  repeatedly  observed  the  presence  of  an  unexpected  55  kDa  protein  on  
the  western  blots.  This  protein  is  believed  to  be  an  uncharacterized  synaptopodin-2  isoform  that  
probably  utilizes  an  alternative  start  site  further  downstream  than  the  myopodin  start  site.  Three  
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possible  alternative  start  sites  were  determined  after  analyzing  the  amino  acid  sequence  that  
would  yield  proteins  of  64  kDa,  63  kDa,  or  54  kDa.   
Myopodin’s  localization  through  immunofluorescence   
To  determine  the  domain  of  expression  of  myopodin  within  HT29  cells,  we  performed  
immunohistochemistry  with  the  same  antibody  used  for  the  western  blot  analysis.  The  
immunofluorescence  was  mainly  localized  in  the  nuclei  of  proliferating  HT29  cells.  The  
immunofluorescence  was  more  intense  in  punctate  spots  within  the  nucleus.  The  pattern  
observed  was  reminiscent  of  nucleoli  localization.  To  confirm  the  nucleolar  localization,  we  
performed  double  staining  experiments  in  which  the  cells  were  also  stained  with  DAPI  (Figure  
6A).  DAPI  is  a  DNA  stain  that  does  not  stain  the  nucleoli  which  mainly  contain  RNA  molecules.  
The  double  staining  experiment  showed  that  the  intense  spots  recognized  by  the  NC_781  
corresponded  to  regions  not  stained  by  DAPI.   These  results  suggested  that  myopodin  was  
expressed  in  the  nucleoli.  We  also  showed  that  myopodin  colocalizes  with  nucleolin,  a  nucleolar  
protein  (Figure  6B).   
After  analyzing  several  images  of  myopodin  with  nucleolin  and  DAPI,  it  became  
apparent  that  myopodin  expression  was  not  exclusively  limited  to  nucleolar  regions.  A  small  
percentage  of  instances  analyzed  showed  that  occasionally  (11%)  myopodin  expression  in  the  
nucleus  was  not  exclusive  to  the  areas  not  stained  with  DAPI  (Figure  6A  arrowheads  and  C)  or  
with  nucleolar  expression  (data  not  shown).  Also,  in  a  smaller  percentage  of  instances  (6%),  a  
nucleolar  region  was  expressed  without  corresponding  to  myopodin  expression  (Figure  6A  thick  
arrows  and  C).  However,  a  majority  of  myopodin’s  expression  (83%)  was  localized  with  the  




Figure  5:  Expression  pattern  of  Synpo2  in  whole  cell  extracts  from  HT29  
cells  through  RT-PCR  and  Western  blot  analysis   
  
  
Figure  5:  Expression  of  Synaptopodin-2  in  HT29  cells.  (A)  A  schematic  representation  of  
where  the  primers  are  designed  to  amplify  the  full-length  open  reading  frame  of  isoform  B  and  
myopodin  anneal.  (B)  RT-PCR  results  using  primers  described  in  A  to  amplify  isoform  B  (lanes  2  
and  3)  and  myopodin  (lanes  4  and  5).  Lanes  2  and  4  were  positive  controls  for  isoform  B  and  
myopodin,  respectively,  using  human  skeletal  muscle  cDNA.  Lanes  3  and  5  were  run  from  HT29  
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Figure  6:  Immunofluorescence  using  a  Synpo2  isoform  specific  antibody  in  
undifferentiated  HT29  cells 
  
Figure  6:  Immunofluorescence  of  myopodin  in  HT29  cells.  (A)  The  NC_781  antibody  
recognizes  an  epitope  specific  for  myopodin  and  was  double  stained  with  DAPI  to  show  nuclear  
localization.  (B)  Myopodin  colocalizes  with  nucleolin.  Arrows  highlight  colocalization  of  
myopodin  with  nucleolin;  arrowheads  highlight  dark  regions  in  DAPI  stain  that  do  not  correspond  
to  myopodin  expression;  thick  arrows  highlight  myopodin  expression  that  does  not  correspond  
to  dark  regions  of  DAPI  stain.  (C)  Statistical  analysis  of  myopodin  and  nucleolin  expression  
pattern  compared  to  its  colocalization.  Statistical  significance  was  determined  by  a  two-tailed  
t-test  and  denoted  by  *  (p  <0.05).   
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Verification  of  nucleolar  localization   
In  order  to  confirm  the  expression  of  myopodin  obtained  with  the  NC_781  antibody  was  
truly  nucleolar  and  not  expressed  on  the  nuclear  membrane,  a  3-dimensional  image  was  taken  
of  the  HT29  cells  using  NC_781  and  DAPI  (data  not  shown).  Another  way  we  confirmed  
myopodin’s  nucleolar  expression  was  to  analyze  its  change  in  expression  upon  transcriptional  
inhibition.  Nucleolar  proteins  will  change  in  expression,  by  either  increasing,  decreasing,  or  
translocating  throughout  the  cell  when  transcription  is  inhibited.  To  inhibit  transcriptional  activity,  
HT29  cells  were  treated  with  actinomycin  D  and  the  expression  of  myopodin  was  analyzed  at  2,  
4,  and  8  hours  after  treatment  (Figure  7).  Myopodin’s  expression  went  from  being  predominantly  
nucleolar  to  diffuse  nuclear  2  hours  post  transcriptional  inhibition  (Figure  7A).  The  expression  of  
myopodin  remained  nuclear  at  4  and  8  hours  after  treatment  (Figure  7B  &  C).  This  change  in  
expression  further  verifies  that  myopodin  is  a  nucleolar  protein.  
Myopodin  expression  through  Western  blot  analysis  
After  analyzing  the  expression  pattern  of  myopodin  through  immunofluorescence,  
Western  blot  analysis  was  performed  on  nuclear  and  cytoplasmic  extracts  from  the  HT29  cells  
to  confirm  nuclear  expression  of  myopodin.  Surprisingly,  myopodin  was  expressed  
predominantly  in  the  cytoplasmic  extract,  which  was  never  seen  through  immunofluorescence.  
However,  an  undescribed  55  kDa  Synpo2  variant  was  expressed  exclusively  in  the  nuclear  
extract  (Figure  8).  These  data  suggest  a  possible  sixth  undescribed  synaptopodin-2  isoform  that  
the  NC_781  antibody  recognizes  through  immunofluorescence  predominantly  in  the  nucleolus,  
that  is  not  isoform  B  or  myopodin.   
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Figure  7:  Transcriptional  inhibition  through  Actinomycin  D  treatment  
disrupts  nucleolar  localization  of  specific  Synpo2  isoforms  
Figure  7:  Nucleolar  localization  disrupted  through  transcriptional  inhibition  (A)  Two  hours  
post  actinomycin  D  treatment;  (B)  four  hours  post  actinomycin  D  treatment;  (C)  eight  hours  post  
actinomycin  D  treatment.  HT29  cells  were  imaged  through  immunofluorescence  using  the  












Immunofluorescence  using  a  non-isoform  specific  antibody  
A  non-isoform  specific  antibody  of  synaptopodin-2  (pan  antibody)  was  used  to  compare  
its  expression  pattern  to  that  of  the  NC_781  isoform  specific  antibody.  The  pan  antibody  was  
capable  of  recognizing  all  known  synaptopodin-2  isoforms,  except  for  the  smallest  unnamed  
isoform  that  lacks  exon  4a.  The  expression  pattern  of  NC_781  (Figure  9A)  was  distinctly  
different  from  that  of  the  non-isoform  specific  expression  pattern  of  synaptopodin-2  (Figure  9B).  
The  expression  of  NC_781  was  exclusively  located  within  the  nucleus,  with  intensely  stained  
and  well-defined  punctate  spots  in  every  cell  (Figure  9A),  whereas  the  expression  pattern  with  
the  pan  antibody  was  notably  absent  from  the  nucleus  and  almost  solely  expressed  in  the  
cytoplasm  (Figure  9B).   
One  possible  explanation  for  the  difference  in  expression  patterns  is  that  the  smaller,  
approximately  55  kDa  protein  seen  through  Western  blot,  lacks  the  epitope  for  the  pan  antibody.  
There  are  three  possible  alternative  start  sites  that  were  identified  through  sequence  analysis  
that  would  yield  proteins  of  approximately  64  kDa,  63  kDa,  and  54  kDa  (Figure  9C).  The  start  
site  that  would  produce  a  54  kDa  protein  only  contains  a  small  portion  of  the  pan  antibody  
epitope.  However,  the  start  sites  that  would  produce  either  a  64  kDa  or  a  63  kDa  protein  would  
also  possess  the  pan  antibody  epitope  (Figure  9C).  When  using  the  pan  antibody  for  Western  
blot  analysis,  similar  75  kDa  and  approximately  55  kDa  banding  patterns  are  obtained  (data  not  
shown).  This  suggests  that  the  unknown  55  kDa  protein  possess  both  the  NC_781  and  the  pan  
antibody  epitope;  however,  no  known  synaptopodin-2  isoform  would  be  able  to  account  for  the  
differences  in  expression  pattern  through  immunofluorescence,  yet  show  similar  expression  
through  Western  blot  analysis.  
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Figure  8:  Western  blot  of  nuclear  and  cytoplasmic  fractions  from  HT29  cells  
using  isoform  specific  antibody  
Figure  8:  Western  blot  analysis  of  HT29  nuclear  and  cytoplasmic  fractions.  Comparing  
nuclear  and  cytoplasmic  extracts  from  HT29  cells,  using  the  NC_781  antibody  shows  a  robust  
cytoplasmic  band  for  myopodin.  The  unknown  55  kDa  protein  was  exclusively  localized  to  the  







Change  in  expression  upon  differentiation  
In  order  to  determine  the  change  of  expression  upon  cell  differentiation,  
immunocytochemistry  was  performed  on  HT29  cells  that  had  been  exposed  to  differentiation  
media  (5  mM  sodium  butyrate)  for  3,  5,  and  7  days.  Upon  cell  differentiation,  the  NC_781  
expression  pattern  went  from  being  entirely  nuclear,  and  predominantly  nucleolar  (Figure  6A),  to  
a  diffuse  nuclear  by  days  3-5  (Figure  10A),  and  ultimately  expressing  exclusively  in  the  
cytoplasm  by  day  7  (Figure  10C).  This  change  in  expression  suggested  a  translocation  from  the  
nucleoli  of  undifferentiated  cells  to  the  cytoplasm  upon  differentiation,  using  the  NC_781  
antibody.  Interestingly,  the  NC_781  expression  banding  pattern  did  not  change  upon  
differentiation  in  Western  blot  analysis  (Figure  10D).  The  only  change  detected  through  Western  
blot  analysis  was  a  decrease  in  intensity  of  bands  upon  differentiation  compared  to  
undifferentiated  cells.  When  considering  the  change  in  expression  pattern  through  
immunofluorescence,  but  the  lack  of  change  through  Western  blot,  this  data  suggests  that  
synaptopodin-2  isoforms  are  not  what  is  shuttling  between  cell  compartments;  but  rather  
epitopes  are  either  becoming  exposed  to  allow  antibody  binding  or  are  being  masked  through  




Figure  9:  Expression  of  NC_781  isoform  specific  antibody  compared  to  
Synpo2  pan  antibody  expression  pattern  in  HT29  cells  
  
Figure  9:  Expression  of  isoform  specific  antibody  compared  to  non-isoform  specific  
expression  pattern.  (A)  The  NC_781  antibody  is  specific  for  an  epitope  encoded  by  the  4b  
exon  of  myopodin  (highlighted  by  the  schematic  in  C).  (B)  The  Pan  antibody  is  non-isoform  
specific,  recognizing  an  epitope  on  exon  4a,  which  is  common  to  4  of  the  5  known  
synaptopodin-2  isoforms.  (C)  A  schematic  representation  of  where  epitopes  are  located  on  the  
gene,  as  well  as  possible  alternative  start  sites  that  would  result  in  a  new  synaptopodin-2  







Figure  10:  Change  in  Synpo2  expression  pattern  upon  differentiation  
of  HT29  cells  
  
                       
Figure  10:  Change  in  Synpo2  expression  pattern  upon  differentiation  of  HT29  cells.  (A)  3  
Days  pdt  shows  an  initial  change  in  the  expression  pattern  of  NC_781  from  nucleolar  to  a  
diffuse  nuclear  and  even  cytoplasmic.  After  5  days  of  treatment  (B)  nucleolar  expression  is  even  
more  dispersed  and  by  a  full  week  of  treatment,  (C)  expression  pattern  is  solely  localized  to  the  
cytoplasm.  Pdt  =  post  differentiation  treatment.  (D)  Western  blot  analysis  using  the  NC_781  
antibody  to  compare  expression  of  differentiated  and  undifferentiated  HT29  cells.  
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DISCUSSION   
It  has  been  suggested  that  synaptopodin-2  has  several  possible  roles  within  the  cell  
(Asanuma  et  al.,  2005;  Beall  &  Chalovich,  2001;  Yu  &  Luo,  2006;  Schroeter  &  Chalovich,  2004;  
Kołakowski  et  al. ,  2004;  Kai  et  al.,  2012).  Research  groups  have  categorized  synaptopodin-2  
as  a  tumor  suppressor  because  of  its  decreased  expression  in  urothelial  cancer  
(Sanchez-Carbayo  et  al.,  2003)  or  its  inactivation  of  expression  in  prostate  cancer  (Yu  et  al.,  
2006).  Other  groups  have  suggested  a  contradicting  role  for  synaptopodin-2  as  a  tumor  
activator,  because  over  expression  of  synaptopodin-2  in  normally  non-invasive  human  
endothelial  kidney  or  mouse  myoblast  cells  increased  the  cells  invasiveness  into  a  collagen  
matrix  (Van  Impe  et  al.,  2003;  De  Ganck  et  al.,  2009).  Realizing  that  synaptopodin-2  isoforms  
respond  differently  to  chemokinetic  stimuli  (Kai  et  al.,  2012)  implies  the  possibility  of  their  
functionally  discrete  roles  within  the  cell.  This  study  focused  on  the  expression  profile  of  
synaptopodin-2  isoform  B  and  myopodin,  to  better  understand  their  effects  within  a  colorectal  
cancer  cell  line.  Synaptopodin-2  isoform  B  and  myopodin  are  the  only  two  synaptopodin-2  
isoforms  that  possess  the  same  full-length  C-terminal  exon  4B;  however,  myopodin  is  
truncated  at  the  amino  terminus  and  is  completely  missing  exon  1-3,  as  well  as  a  portion  of  
exon  4A.  For  the  purpose  of  this  study,  synaptopodin-2  isoform  B  and  myopodin  were  analyzed  
in  colon  cancer  HT29  cells.   
Our  goal  was  to  study  the  expression  of  isoform  B  and  myopodin  at  an  mRNA  and  
protein  level  within  the  cell  using  PCR,  Western  blot  and  immunofluorescence  with  the  antibody  
NC_781  that  was  specific  for  exon  4B.  Other  groups  have  suggested  that  synaptopodin-2  
resides  in  the  nucleus  (Weins  et  al.,  2001;  Faul  et  al.,  2007;  Cebrian  et  al.,  2008;  
Pompas-Veganzones  et  al.,  2016 ).  Interestingly,  our  lab  has  previously  shown  that  Synpo2  
isoforms  A  and  D  are  exclusively  expressed  in  the  cytoplasm  of  HT29  (Shortt,  unpublished  
data).  In  this  study  we  saw  no  expression  for  isoform  B  in  undifferentiated  or  differentiated  
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HT29  cells.  However,  myopodin,  the  smallest  named  Synpo2  isoform,  was  expressed  in  HT29  
cells  at  an  mRNA  and  protein  level  in  the  nucleus  of  undifferentiated  and  differentiated  cells.  
Unexpectedly,  we  detected  an  unknown  protein  of  approximately  55  kDa,  in  addition  to  
myopodin  at  75  kDa,  through  Western  blot  analysis  using  an  exon  4B  specific  antibody,  
NC_781.  The  NC_781  antibody  was  raised  against  the  9  amino  acid  peptide  of  exon  4B  and  
affinity  purified.  Despite  the  specificity  of  the  NC_781  antibody  for  Synpo2  exon  4B,  
cross-reactivity  of  the  antibody  needs  to  be  considered.  There  are  several  55  kDa  nucleolar  
proteins  whose  sequences  were  examined  for  potential  cross-reactivity  with  the  NC_781  
antibody.  However,  BLAST  analysis  showed  no  other  protein  with  a  similar  sequence  that  
would  be  able  to  act  as  an  epitope  for  this  antibody.  These  results  suggest  the  55  kDa  protein  
is  another  Synpo2  isoform.  For  the  purpose  of  this  discussion,  we  will  refer  to  this  possible  
Synpo2  isoform  as  variant  X.  
Initial  immunofluorescence  data  gathered  from  undifferentiated  HT29  cells  revealed  all  
expression  detected  by  the  NC_781  antibody  was  exclusively  nuclear,  and  even  more  
interestingly,  it  was  predominantly  nucleolar.  To  our  knowledge  this  is  the  first  report  of 
nucleolar  localization  of  any  synaptopodin-2  isoform,  which  suggests  possible  transcriptional  
regulation  activity  within  the  cell.  As  a  way  to  confirm  nucleolar  expression  detected  with  the  
NC_781  antibody,  we  were  able  to  show  colocalization  of  nucleolin  (a  well-documented  
nucleolar  expressed  protein)  with  the  nucleolar  expression  detected  by  the  NC_781  antibody.  
Additionally,  we  inhibited  transcriptional  activity  of  HT29  cells  by  treating  them  with  actinomycin  
D  for  2,  4,  and  8  hours.  The  nucleolar  localization  exhibited  in  untreated  cells  was  lost  and  a  
more  diffuse  nuclear  distribution  was  detected.  These  results  verified  the  protein  recognized  by  
NC_781  through  immunofluorescence  as  a  nucleolar  protein.   
When  nuclear  and  cytoplasmic  extracts  were  made  from  undifferentiated  HT29  cells,  
we  expected  to  see  a  band  corresponding  to  the  size  of  myopodin  intensely  expressed  in  the  
nuclear  extract  and  no  expression  in  the  cytoplasmic  extract.  These  results  would  support  the  
data  collected  through  immunofluorescence.  Surprisingly,  an  extremely  robust  75  kDa  band,  
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which  corresponds  to  myopodin,  was  seen  in  the  cytoplasmic  extract  and  only  a  faint  band  was  
detected  in  the  nuclear  compartment.  Another  unexpected  piece  of  data  that  was  provided  
through  the  Western  blot  was  the  detection  of  a  smaller,  undescribed  55  kDa  (variant  X)  protein  
that  was  exclusively  and  intensely  expressed  in  the  nuclear  extract.  Western  blot  using  
nucleolar  extracts  made  from  HT29  cells  (data  not  shown)  showed  an  extremely  robust  band  at  
approximately  55  kDa  and  nothing  that  would  correspond  to  myopodin.  These  data  suggest  
that  it  is  the  undescribed  variant  X  that  is  actually  localizing  within  the  nucleolus,  not  myopodin.  
Similar  to  the  results  reported  by  Weins  et  al.  in  mouse  myoblast  cells  (2001),  our  
immunofluorescence  data  shows  myopodin  is  localized  in  the  nucleus  of  undifferentiated  cells  
but  is  predominantly  expressed  in  the  cytoplasm  upon  differentiation.  These  findings  would  
support  myopodin’s  role  as  a  tumor  suppressor,  which  is  supported  by  previously  unpublished  
data  we  collected  that  showed  the  overexpression  of  myopodin  in  Hela  cells  resulted  in  
reduced  proliferation  rates  (Harkins,  unpublished  data).  Our  immunofluorescence  images  
support  a  change  in  expression  pattern  from  undifferentiated  to  differentiated  HT29  cells.  This  
change  in  myopodin  expression  upon  differentiation  may  affect  cell  cycle  activity  through  its 
association  with  the  actin  cytoskeleton.  The  possible  undescribed  Synpo2  isoform,  variant  X,  
which  was  shown  to  be  expressed  largely  in  the  nucleolus  of  undifferentiated  HT29  cells  
through  immunofluorescence,  was  dramatically  reduced  upon  cell  differentiation,  in  agreement  
with  our  Western  blot  data.  Interestingly,  this  55  kDa  protein  was  never  detected  in  cytoplasmic  
extracts  analyzed  through  Western  blot,  regardless  of  the  cell's  state  of  differentiation.  The  only  
notable  changes  from  undifferentiated  nuclear  and  cytoplasmic  protein  extracts  to  differentiated  
nuclear  and  cytoplasmic  protein  extracts  were  from  variability  in  band  intensities,  as  there  was  
no  change  in  the  banding  pattern  detected  through  Western  blot.  This  suggests  the  
cytoplasmic  expression  observed  by  immunofluorescence  upon  differentiation  is  solely  
attributed  to  changes  in  myopodin  through  transcription/translation  and  not  translocation.   
It  is  remarkable  that  cytoplasmic  extracts  yield  a  more  robust  band  through  Western  
blot  in  undifferentiated  HT29  cells  compared  to  expression  of  differentiated  cells,  because  our  
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immunofluorescence  data  (which  used  the  same  antibody)  detected  virtually  no  cytoplasmic  
expression  in  undifferentiated  HT29  cells.  One  possible  explanation  for  this  discrepancy  could  
be  attributed  to  the  hub  protein  properties  associated  with  synaptopodin  family  members.  It  is  
reasonable  to  consider  that  myopodin  expression  in  the  cytoplasm  is  not  detected  through  
immunofluorescence  because  the  NC_781  antibody  epitope  is  blocked  by  any  one  of  
myopodin’s  several  known  binding  partners.  However,  the  denaturation  process  involved  with  
Western  blot  analysis  would  dissociate  myopodin  from  its  binding  partners,  allowing  the  
antibody  access  to  the  epitope.  
Recent  studies  have  suggested  the  importance  of  maintaining  the  appropriate  ratio  of  
cytoplasmic  Synpo2  to  nuclear  Synpo2  for  proper  cell  function  (Gao  et  al.,  2020).  Loss  of  
nuclear  Synpo2  expression  has  been  associated  with  poor  clinical  outcomes  in  bladder  cancer  
(Carbayo-Sanchez  et  al.,  2003).  Additionally,  increased  cytoplasmic  expression  to  nuclear  
expression  of  Synpo2  has  been  correlated  to  a  significantly  higher  reassurance  rate  of  liver  
cancer  (Gao  et  al.,  2020).  However,  this  data  was  collected  using  a  non-isoform  specific  region  
of  the  Synpo2  genome.  To  our  knowledge,  this  study  is  the  first  to  suggest  that  changes  in  
cytoplasmic  and  nuclear  expression  of  Synpo2  is  not  solely  attributed  to  nuclear-cytoplasmic  
translocation,  but  instead  to  changing  compartmental  levels  of  isoform  expression.  Our  
laboratory  has  previously  reported  that  the  role  Synpo2  plays,  as  either  a  tumor  suppressor  or 
activator,  is  isoform  dependent  (Shortt,  unpublished  data).  Understanding  the  changes  in  
expression  of  individual  Synpo2  isoforms  is  critical  to  better  understand  the  overall  function  it  
has  within  the  cell.   
Using  the  NC_781  antibody,  designed  exclusively  to  detect  Synpo2  isoform  B  and  
myopodin  expression,  we  detected  nucleolar  expression  of  a  possible  uncharacterized  Synpo2  
isoform  at  55  kDa.  To  our  knowledge,  our  lab  is  the  first  to  detect  nucleolar  expression  of  this  
synaptopodin-like  protein.  The  nucleolar  synaptopodin-like  expression  we  saw  in  
undifferentiated  HT29  cells  suggests  a  highly  critical  role  for  normal  cell  function.  Nucleoli  are  
prominent  substructures  located  within  the  nuclei  of  cells  and  are  connected  to  cell  growth,  
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division,  and  proliferation.  The  nucleoli  have  been  predominantly  associated  with  the  
biogenesis  of  rRNA  by  RNA  polymerase  I  and  the  assembly  of  ribosomal  subunits  (Busch  &  
Smetana,  1970;  Hadjiolov,  1985).  It  is  estimated  that  rRNA  synthesis  accounts  for  
approximately  50%  of  the  total  RNA  production  in  an  actively  growing  and  dividing  cell  (Zylber  
&  Penman,  1971).  If  expression  of  Synpo2  has  an  effect  on  rRNA  synthesis,  then  by  
association  it  would  affect  the  cells  ability  to  proliferate.  In  addition  to  its  ribosomal  production  
role  of  the  nucleoli,  it  has  become  evident;  the  nucleolus  is  not  limited  to  these  functions.  Over  
700  proteins  have  been  characterized  within  or  in  association  with  these  structures  and  still  a  
significantly  large  number  of  uncharacterized/novel  proteins  that  are  yet  to  be  described  for  
their  role  within  the  nucleolus  ( Boisvert  et  al.,  2007 ).  Our  findings  suggest  the  novel  nucleolar  
expression  of  the  previously  uncharacterized  Synpo2  isoform  may  be  critical  for  normal  cell  
function.   
In  agreement  with  our  labs  previous  findings,  it  seems  the  effects  of  Synaptopodin-2  as  
either  a  tumor  suppressor  or  activator  are  isoform  dependent,  as  the  expression  of  individual  
isoforms  are  altered  through  differentiation.  These  findings,  along  with  the  nucleolar  localization  
of  Variant  X,  suggest  a  more  complex  role  for  Synaptopodin-2  in  cell  cycle  progression  than  









CHAPTER  3:  MATERIALS  AND  METHODS  
  
Cell  Culture   
HT29  cells  were  obtained  from  ATCC  (Cat  number:  HTB38)  and  were  used  as  the  model  
for  this  research  project.  For  normal  cell  culture,  the  HT29  cell  line  was  cultured  in  DMEM/F12  
(Invitrogen),  supplemented  with  10%  fetal  bovine  serum  (FBS),  penicillin  and  streptomycin  
(100U  and  100  µg/ml,  respectively).  Normal  cell  conditions  were  37°C  in  a  humidified  CO 2   
incubator  (5  %  CO 2 ).   
HT29  Differentiation  
HT29  cells  were  differentiated  using  sodium  butyrate,  following  a  previously  described  
protocol  (Augerson  and  Laboisse,  1984).  Cells  were  seeded  on  coverslips  that  were  placed  in  
35mm  Petri  dishes.  For  each  Petri  dish,  750,000  cells  were  plated  and  allowed  to  adhere  and  
proliferate  in  normal  DMEM/F12  for  48  hours.  The  normal  media  was  aspirated  then  replaced  
with  normal  DMEM/F12  media  supplemented  with  sodium  butyrate  at  a  5  mM  final  
concentration.  The  cells  were  maintained  in  sodium  butyrate  supplemented  media  that  was  
changed  daily  for  7  days.   
RNA  Extraction  
RNA  was  extracted  from  cells  in  culture  using  the  following  procedure  and  reagents  from  
the  RNeasy  kit  (Qiagen).  Cells  were  grown  in  T75cm 2  flasks  until  90%  confluent.  Once  cells  
reached  approximately  5  million  total  cells,  the  media  was  removed  and  cells  were  washed  with  
5  mL  with  1X  phosphate  buffered  saline  (PBS).  After  removing  the  1X  PBS,  cells  were  detached  
  
using  0.05%  trypsin  in  EDTA  (Gibco).  Once  the  cells  had  detached,  5  ml  of  complete  
DMEM/F12  media  was  added  to  the  flask.  The  cells  were  transferred  into  an  RNase-free  
microcentrifuge  tube  and  were  pelleted  at  300  x  g  for  5  minutes.  The  supernatant  was  
completely  aspirated  and  600  µl  of  Buffer  RLT  was  added  and  mixed  thoroughly  to  resuspend  
the  pellet.  The  cell  lysate  was  then  homogenized  by  passing  the  solution  through  a  20-gauge  
needle  5  times.  One  volume  of  70%  ethanol  was  added  to  the  homogenized  lysate  and  mixes  
well  through  pipetting.  The  homogenized  lysate  was  then  transferred  to  an  RNeasy  spin  column,  
placed  in  a  2  ml  collection  tube,  and  was  centrifuged  at  1,000  x  g  for  15  seconds.  The  
flow-through  was  discarded.  Next,  700  µl  of  Buffer  RW1  was  added  to  the  spin  column  and  
centrifuged  again  at  1,000  x  g  for  15  seconds.  The  flow-through  was  again  discarded.  To  the  
spin  column,  500  µl  of  Buffer  RPE  was  added  and  centrifuged  again  for  15  seconds  at  1,000  x  
g .   An  additional  Buffer  RPE  wash  was  performed  except  that  the  column  was  spun  for  2  
minutes  at  1,000  x  g .  A  dry  spin  was  then  performed  for  1  minute  at  1,000  x  g  to  ensure  all  the  
ethanol  from  the  wash  solution  was  removed  from  the  spin  column  membrane.  The  spin  column 
was  then  placed  in  a  new  1.5  ml  collection  tube  and  50  µl  of  RNase-free  water  was  added  
directly  to  the  membrane  of  the  column  and  allowed  to  incubate  at  room  temperature  for  1  
minute.  The  RNA  was  then  eluted  from  the  spin  columns  membrane  by  centrifuging  for  1  minute  
at  full  speed.  The  total  RNA  extracted  was  quantified  using  the  NanoDrop  2000  (Thermo  
Scientific)  and  stored  at  -80°C.  
cDNA  Synthesis  
Total  RNA  was  used  to  synthesize  cDNA,  after  first  undergoing  a  DNase  treatment  to  
remove  any  genomic  DNA  contamination  (Turbo  DNase  Kit,  Ambion).  In  brief,  to  a  5  µg  solution  
of  RNA  sample,  0.1  volume  of  10X  TURBO  DNase  buffer  and  0.5  µl  TURBO  DNase  (2  U/µl)  
was  added,  and  mixed  gently.  The  samples  were  incubated  at  37°C  for  30  minutes  then  an  
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additional  0.5  µl  of  TURBO  DNase  was  added  and  the  samples  were  incubated  at  37°C  for  an  
additional  30  minutes  before  adding  0.1  volume  of  DNase  Inactivation  Reagent.  Samples  were  
incubated  at  room  temperature  for  5  minutes,  mixing  periodically,  before  being  centrifuged  at  
10,000  x  g  for  1.5  minutes  and  the  supernatant  was  transferred  into  a  new  test  tube.  Five  µg  
total  purified  RNA  was  aliquoted  into  0.5  ml  test  tubes.  One  µl  of  50  µM  Oligo(dT) 20    primer  or  1  
µl  of  the  30µM  gene  specific  RT  primer  (5’  GCTAGGCATTCTCAGGGACTCAAG  3’)  and  1  µl  of  
10  mM  dNTP  were  mixed  will  then  added.  The  final  volume  was  adjusted  to  10  µl  with  sterile  
water.  Samples  incubated  at  65°C  for  5  minutes  and  then  were  transferred  to  ice  for  1  minute.  
To  each  RNA/primer  mix  sample,  2  µl  of  10X  RT  buffer,  4  µl  of  25  mM  MgCl₂,  2  µl  of  0.1  M  0.1  
DTT,  1  µl  of  RNase  out  (40  U/µl),  and  1  µl  of  Superscript  III  RT  (200  U/µl)  were  added.  The  
samples  were  then  incubated  for  50  minutes  at  50°C,  and  then  at  85°C  for  5  minutes.  Finally  1  
µL  of  RNase  H  was  added  and  incubated  for  20  minutes  at  37°C.  The  resulting  cDNA  was  
cleaned,  quantified  with  the  NanoDrop  and  stored  at  -20°C.   
Reverse  Transcription  Polymerase  Chain  Reaction  (RT-PCR)   
The  cDNA  synthesized  from  HT29  total  RNA  is  used  as  the  template  for  PCR.  A  PCR  
core  mix  is  prepared  by  combining  15.125  µl  of  sterile  water,  2.5  µl  of  10X  PCR  buffer,  0.75  µl  of  
50  mM  MgCl₂,  0.5  µl  of  10  mM  dNTPs,  and  0.125  µl  of  Taq  polymerase  per  reaction,  in  a  test  
tube.  The  PCR  core  mix  was  then  added  to  individual  0.2  ml  PCR  tubes  that  contained  1  µl  of  
cDNA  template  and  2.5  µl  of  a  30  nM  forward  and  2.5  µl  of  a  30  nM  reverse  primer.  A  negative  
control  tube  was  prepared  in  which  the  cDNA  template  was  omitted  and  1  µl  of  distilled  
autoclaved  water  added.  These  samples  were  placed  in  a  thermocycler.   The  optimal  annealing  
temperatures  for  each  primer  set  was  determined  by  running  a  temperature  gradient  ranging  
from  55-65°C.  The  thermocycler  was  programmed  to  denature  the  cDNA  at  94°C  for  2  minutes,  
then  perform  40  cycles  as  follows:   94°C  for  1  minute,  the  specified  annealing  temperature  for  
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the  primer  set  (Table  2)  for  45  seconds,  and  74°C  for  1.5  minutes  for  elongation.  The  forward  
primers,  for  the  individual  variants,  were  designed  to  anneal  to  a  sequence  in  the  common  4a  
exon  (Figure  1).  Each  reverse  primer  was  designed  to  anneal  to  a  sequence  for  their  unique  
exon  or  in  the  3’  UTR.   PCR  products  were  analyzed  on  an  agarose  gel.  1X  TAE  buffer  (Table  3)  
was  used.  Agarose  gels  were  run  for  1.5  hour  at  90  volts.  
Cloning   
To  analyze  gain  of  function  of  synaptopodin-2  in  HT29  cells,  primers  were  designed  to  
amplify  the  full  length  gene  of  isoform  B  and  the  closely  related  myopodin  (see  primer  
sequences  in  Appendix).  The  forward  primer  was  designed  to  have  a  polymerase  recognition  
clamp  site,  a  HindIII  restriction  enzyme  sequence,  a  Kozak  sequence,  followed  by  the  start  
codon  with  the  first  21  nucleotides  of  the  coding  gene  sequence.  The  reverse  primers  were  
designed  to  anneal  to  the  last  23  nucleotides  in  exon  4b  on  the  3’  end  of  the  gene,  followed  by  a  
3  glycine  spacer,  a  6XHIS-tag,  a  stop  codon,  and  a  BamHI  restriction  enzyme  cleavage  site.   
The  full  length  coding  sequence  was  amplified  through  long  range  PCR,  double  digested  
with  HindII  and  BamHI  restriction  enzymes,  and  ligated  into  the  pcDNA4/TO  vector  (Figure  5).  
After  ligation,  the  clone  was  amplified  using  E.  coli  and  was  selected  for  using  ampicillin.  The  
cloned  sequences  were  confirmed  for  accuracy  through  sequencing.  The  transformed  plasmid  






Figure  11:  pcDNA4/TO  expression  and  pcDNA6/TR  regulatory  vectors  
  
Figure  11:  T-REx  pcDNA4/TO  mammalian  expression  vector  and  the  pcDNA6/TR  
regulatory  vector,  purchased  from  Invitrogen.  BamHI  and  HindIII  restriction  enzyme  sites  












Transfection  into  HT29  Cells   
HT29  cells  were  transfected  using  Lipofectamine  2000  (Invitrogen).   Briefly,  0.5-2  10 5   
cells  were  plated  in  500  µl  of  10%  FBS  supplemented  DMEM/F12  without  antibiotics  in  24  well  
plates  24  hours  before  the  transfection.  The  plasmid  DNA  was  diluted  in  Opti-MEM  I  medium,  
following  the  manufacturer’s  recommendation   (Invitrogen).  The  cells  were  cotransfected  with  
the  pcDNA6/TR  (Figure  5)  (Invitrogen)  at  a  ratio  of  6:1  (w:w)  pcDNA6/TR:pcDNA4/TO  plasmid  
with  DNA  insert.  The  pcDNA6/TR  plasmid  expresses  the  Tet  repressors  that  repressed  
expression  of  the  gene  of  interest  inserted  in  the  pcDNA4/TO  plasmid.  Lipofectamine  2000  
transfection  reagent  was  diluted  in  Opti–MEM  I  medium.   After  incubating  at  room  temperature  
for  5  min,  the  diluted  DNA  was  combined  with  the  diluted  Lipofectamine  2000  in  a  total  volume  
of  100  µl/well  to  achieve  a  1:3  ratio  (DNA  (µg)  to  lipofectamine  (µl)).   After  20  minutes  at  room  
temperature  the  100  µl  of  diluted  DNA  and  Lipofectamine  2000  was  added  to  each  well  
containing  cells  and  medium.  Cells  were  incubated  at  37°C  in  a  CO 2   incubator  for  18-48  hours  
(medium  was  changed  after  4-6  hours).  The  cells  were  passaged  at  a  1:10  ratio  into  fresh  
growth  medium  24  to  48  hours  after  transfection,  and  selected  with  Zeocin  and  Blasticidin  24  
hours  later.  
Cell  Selection  through  Antibiotic  Screening  
  Cell  selection  was  performed  using  Zeocin,  which  upon  activation  will  bind  and  cleave  
DNA,  leading  to  cell  death  in  untransfected  HT29  cells.  The  cells  that  are  Zeocin-resistant  will  
continue  to  grow  and  divide  normally.  In  order  for  accurate  cell  selection,  the  minimum 
concentration  of  Zeocin  required  to  kill  the  HT29  cell  line  was  first  determined  to  be  800  µg/ml.  
This  was  determined  using  a  testable  range  of  concentrations  for  Zeocin,  which  in  mammalian  
cells  is  50-1000  µg/ml.  Briefly,  8,000  cells/well  were  seeded  in  a  96  well-plate  in  normal  media  
for  24  hours.  The  normal  media  was  removed  and  media  with  varying  concentrations  (0,  50,  
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100,  200,  400,  600,  800,  and  1000  µg/ml)  of  Zeocin  was  added.  This  selective  media  was  
changed  every  3-4  days  for  14  days.  The  appropriate  working  concentration  of  Zeocin  in  the  
selective  media  was  the  amount  that  killed  the  majority  of  the  cells  within  2  weeks.  Cells  that  are  
sensitive  to  Zeocin  will  undergo  morphological  changes  (increasing  in  cell  size,  altering  the  cell  
shape,  the  appearance  of  empty  vesicles),  which  eventually  lead  to  a  complete  breakdown  of  
the  cell.  The  selective  media  concentrations  were  performed  in  triplicate.  Cell  viability  was  
determined  through  MTT  assays  (described  below).  
A  double  antibiotic  selection  process  had  to  be  used,  since  cells  were  cotransfected  with  
plasmids  that  differed  in  antibiotic  resistance.  The  pCDNA4/TO  vector  was  screened  for  using  
Zeocin,  whereas  the  pCDNA6/TR  vector  had  to  be  screened  for  using  Blasticidin.  The  minimum  
concentration  of  Blasticidin  was  determined  to  be  7.5  µg/ml,  following  the  selective  procedure  
listed  for  Zeocin,  differing  only  in  the  antibiotic  concentrations  used  (0,  1,  2.5,  5,  7.5,  10,  12.5,  
and  15  µg/ml).  Having  a  dual  selection  process  ensured  that  only  the  cells  that  survived  
possessed  both  plasmids  necessary  to  express  genes  of  interest.   
Generating  Stable  HT29  Cell  Lines  
  
To  generate  stable  HT29  cell  lines  that  were  able  to  inducibly  express  the  gene  of  
interest,  the  cells  were  first  transfected  and  plated  into  100mm  culture  plates.  Once  transfected,  
the  cells  were  washed  with  1X  PBS  and  fresh  complete  DMEM/F12  media  was  then  added  to  
the  cells.  Between  48-72  hours  after  transfection  the  cells  were  split  at  varying  densities  into  
fresh  media  containing  the  selective  Zeocin  and  Blasticidin  antibiotic  concentrations.  The  cells  
were  maintained  in  the  selective  medium,  replenishing  every  3-4  days,  until  the  cell  foci  were  
identified.  The  colonies  that  were  picked  as  viable  were  transferred  to  48-well  plates  then  
allowed  to  grow  to  near  confluency  before  transferring  them  into  a  larger  plate.  The  HT29  cells  
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were  maintained  in  media  containing  800  µg/ml  of  Zeocin  and  7.5  µg/ml  Blasticidin,  to  prevent  
the  growth  of  sensitive  cells.   
MTT  Assay  to  Analyze  Cell  Viability  
In  addition  to  the  growth  curve  to  analyze  cell  growth,  a  
3- (4,5-Dimethylthiazol-2-Yl) -2,5-Diphenyltetrazolium  Bromide  (MTT)  assay  can  be  performed  to  
assess  the  proliferation  and  viability  of  the  cells.  This  is  done  by  seeding  500  cells/100  µl  in  
complete  DMEM/F12  per  well,  in  a  96  well  plate  and  incubating  for  24  hours.  After  incubating,  
the  media  is  removed  and  replaced  with  100  µl  of  fresh,  complete  DMEM/F12  and  10  µl  of  
12mM  MTT  (Ambion).  The  wells  are  not  mixed.  Control  wells  are  also  made  to  contain  100  µl  of  
complete  DMEM/F12  media  and  10  µl  of  MTT.  The  plate  is  incubated  at  37ᵒC  with  5%  CO 2 ,  for  
4  hours.  Samples  are  mixed  with  a  pipette,  avoiding  the  formation  of  bubbles.  The  plate  is  
measured  at  540nm.   
Over  Expression  
The  pcDNA4/TO  expression  vector  contains  two  tetracycline  operator  2  (TetO 2 )  sites  
within  the  cytomegalovirus  (CMV)  promoter,  which  allows  for  tetracycline-regulated  gene  
expression  through  cotransfected  with  the  pcDNA6/TR  vector.  Tet  repressor  molecules,  which  
are  expressed  from  the  pcDNA6/TR  plasmid,  bind  the  TetO 2   sequence  to  prevent  transcription  
of  the  desired  genes.  The  addition  of  tetracycline  to  the  cells  will  reduce  the  repression  of  the  
hybrid  CMV/TetO 2   promoter  in  the  pcDNA4/TO  vector,  which  will  allow  the  cells  to  express  the  
Synpo2  genes  of  interest.  Depending  on  the  efficiency  of  the  transfection,  a  0.1-1  µg/ml  final  
concentration  of  tetracycline  is  used  to  obtain  optimal  expression  of  the  HT29  cell  line.   
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Whole  Cell  Protein  Extraction   
Whole  cell  protein  extracts,  from  HT29  cells,  enabled  further  studies  through  western  
blot  analysis  to  determine  the  expression  of  synaptopodin-2  isoform  B  and/or  myopodin  at  a  
protein  level.  Whole  cell  lysate  was  made  from  HT29  cells.  Sterile  1X  PBS,  the  Nonidet-P40  
(NP-40)  buffer  (20  mM  Tris-HCl  -  pH  7.5,  137mM  NaCl,  2mM  EDTA  -  pH  8,  1%  NP-40,  10%  
Glycerol),  a  rubber  policeman,  and  microcentrifuge  tubes  were  placed  on  ice  20  minutes  prior  to  
extraction  to  chill.   
  The  cells  were  cultured  to  75%  confluency  in  a  T75cm²  flask  before  being  harvested.  To  
harvest  the  cells,  the  media  was  aspirated  and  500ml  of  chilled  1X  PBS  was  added  directly  to  
the  cells  then  quickly  removed.  A  protease  inhibitor  was  added  to  the  ice-cold  NP-40  buffer  just  
prior  to  adding  it  directly  to  the  flask.  For  a  T75cm²  flask  at  75%  confluency,  which  is  
approximately  5x10⁶  cells,  0.5  ml  of  NP-40  buffer  was  used.  The  pre-chilled  rubber  policeman  
was  used  to  scrap  the  cells  from  the  flask.  The  chilled  NP-40  buffer,  with  the  suspended  cells,  
was  transferred  to  a  pre-cooled  microcentrifuge  tube.  Samples  were  incubated  for  30  minutes  
under  a  constant  agitation,  at  4ᵒC,  followed  by  centrifugation  for  20  minutes,  at  12,000  rpm  at  
4ᵒC,  then  transferred  to  ice.  The  pellet  was  found  to  contain  the  proteins  of  interest.  Lysate  
samples  were  stored  at  -80ᵒC.   
Nuclear  and  Cytoplasmic  Protein  Extraction   
To  analyze  the  location  of  specific  proteins  in  either  the  cytoplasm  or  the  nucleus,  a  
nuclear/cytoplasmic  extraction  was  required.  Following  the  NE-PER  Nuclear  and  Cytoplasmic  
Extraction  kit  (Thermo  Scientific,  78835),  adherent  cells  were  harvested  with  trypsin-EDTA  and  
centrifuged  for  5  minutes  at  500  x  g.  Cells  were  washed  in  1X  PBS  then  5  x  10 6    cells  were  
transferred  to  a  1.5  ml  microcentrifuge  tube.  The  cells  were  pelleted  by  centrifugation  at  500  x  g  
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for  3  minutes  and  the  supernatant  was  discarded,  leaving  the  pellet  as  dry  as  possible.  To  the  
cell  pellet,  500  µl  of  pre-chilled,  ice-cold  CER  I  buffer  was  added  then  vortexed  vigorously  until  
the  cell  pellet  was  fully  suspended.  The  cell  suspension  was  placed  on  ice  to  incubate  for  10  
minutes.  After  the  incubation,  27.5  µl  of  pre-chilled,  ice-cold  CER  II  buffer  was  added  to  the  cell  
suspension.  Samples  were  vortexed  for  5  seconds  and  placed  on  ice  for  1  minute.  Samples  
were  vortexed  again  for  an  additional  5  seconds  then  were  centrifuged  for  5  minutes  at  16,000  x  
g.  The  supernatant  was  immediately  transferred  into  a  pre-chilled  1.5  microcentrifuge  tube.  A  1  
µl  aliquot  was  taken  from  the  supernatant  and  a  small  amount  of  the  pellet  was  taken  to  the  
microscope  to  ensure  purity  of  the  extraction.  The  supernatant  was  stored  as  the  cytoplasmic  
extracts.  To  the  pellet,  500  µl  of  ice-cold  NER  buffer  was  added  and  samples  were  mixed  
vigorously  by  vortex  for  15  seconds.  The  sample  was  placed  on  ice  and  was  vortexed  for  15  
seconds  every  10  minutes,  for  40  total  minutes.  After  the  40  minutes,  samples  were  centrifuged  
for  10  minutes  at  16,000  x  g.  The  supernatant  containing  the  nuclear  extract  was  immediately  
transferred  to  a  pre-chilled  tube,  analyzed  under  the  microscope  and  stored  at  -80°C.   
  
Western  Blot  Analysis  
Protein  analysis  from  whole  cell,  nuclear,  and  cytoplasmic  extracts  were  performed  
through  Western  blot.  In  order  to  perform  Western  blot  analysis,  proteins  were  first  separated  by  
size  through  SDS-PAGE.   
Protein  Sample  Preparation   
Protein  concentrations  were  determined  before  analysis  through  SDS-PAGE  following  
the  Pierce  Assay  (Thermo  Scientific)  protocol,  using  BSA  dilutions  to  provide  a  standard  curve.  
Protease  inhibitor  was  added  directly  to  2X  Laemmli  buffer  (0.125M  Tris-HCl  pH  6.8,  10%  
2-mercaptoethanol,  20%  glycerol,  0.0004%  bromophenol  blue,  4%  SDS)  prior  to  use.  The  2X  
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Laemmli  buffer  was  added  at  a  1:1  ratio  to  the  cell  lysate  sample  then  boiled  for  5  minutes.  Any  
precipitation  on  the  lid  of  the  test  tubes  was  collected  by  quick  centrifugation.  
SDS-PAGE  
The  BioRad  mini-PROTEAN  Tetra  Cell  was  used  to  prepare  and  run  all  SDS-PAGE.  A  
6%  Bis-acrylamide  resolving  gel  (1.5M  Tris-HCl,  pH  8.8)  and  a  4%  (0.5M  Tris-HCl,  pH  6.8)  
stacking  gel  were  prepared  for  ideal  separation  for  the  proteins  of  interest.  Gels  were  prepared  
according  to  the  manufacturer’s  instructions  (Invitrogen).  When  preparing  the  resolving  gel,  10%  
APS  and  TEMED  were  added  and  gently  swirled  immediately  before  pouring  between  the  two  
glass  plates  (approximately  4.5  ml).  Double  distilled  water  was  then  added  directly  on  top  of  the  
monomer  solution.  After  allowing  the  resolving  gel  to  polymerize  at  room  temperature  for  at  
least  one  hour,  the  water  layer  was  removed  and  replaced  with  the  4%  stacking  gel  with  the  
addition  of  a  10  well  comb.  The  stacking  gel  was  allowed  to  polymerize  for  at  least  two  hours  
before  use.   
Before  loading  the  gel,  the  apparatus  was  filled  with  prepared  Electrode  (Running)  Buffer  
(25  mM  Tris-HCl,  192mM  glycine,  0.1%  SDS  –  pH  8.3;  see  recipes  in  Appendix).  Prepared  
protein  samples  were  loaded  at  a  30  µg  final  concentration,  along  with  the  BioRad  molecular  
weight  marker  (Precision  Plus  Protein  Dual  Color  Standard),  which  was  run  in  parallel  to  the  
protein  extracts.  The  gel  was  run  at  a  constant  90V  until  the  loading  buffer  reached  the  bottom  
of  the  resolving  gel.  Once  electrophoresis  was  completed,  the  gel  could  be  stained  with  Imperial  
Protein  Stain  (Pierce)  overnight  to  analyze  protein  separation,  or  the  gel  was  immediately  used  
for  Western  blot  analysis.  
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Western  Blot  
A  semi-dry  transfer  method  was  used  to  transfer  the  proteins  from  the  SDS-PAGE  to  a  
Polyvinylidene  fluoride  (PDVF)  membrane  (Millipore),  to  determine  if  the  HT29  cell  lysate  
contained  the  proteins  of  interest.  The  expression  of  the  isoform  B  and  myopodin  was  studied  
using  an  antibody  provided  by  Dr.  Chaolvich,  at  East  Carolina  University.  The  isoform  
B/myopodin  specific  antibody,  denoted  as  NC_781,  is  a  polyclonal  antibody  that  was  raised  in  
rabbits  against  exon  4b  (amino  acid  sequence:  VWKPSVVEE)  and  affinity  purified.  The  NC_781  
antibody  (3  mg/ml)  was  used  at  a  1:2,000  dilution.  Beta-actin  was  used  as  a  positive  control  
(Sigma,  A1978).  A  non-isoform  specific  synaptopodin-2  antibody  was  purchased  from  abcam  
(ab50192)  to  use  as  a  comparison  in  expression  patterns.  Both  secondary  antibodies,  goat  
anti-mouse  (12-349)  and  goat  anti-rabbit  (12-348),  were  purchased  from  Millipore  and  were  
horseradish  peroxidase  conjugated.  Aside  from  the  NC_781  antibody,  working  dilutions  were  
used  at  the  manufacturer's  recommendations.  
To  prepare  for  the  protein  transfer,  the  membrane  and  3  mm  whatman  paper  were  cut  to  
the  dimensions  of  the  gel.  The  gel  was  equilibrated  in  the  continuous  transfer  buffer  (39  mM  
Glycine,  48  mM  Tris,  1.3  mM  SDS,  20%  Methanol  –  pH  9.2;  see  recipe  in  Appendix)  while  
preparing  the  membrane.  To  prepare  the  membrane,  it  is  placed  in  100%  methanol  for  15  
seconds,  transferred  to  double  distilled  water  for  2  minutes,  then  placed  in  the  continuous  
transfer  buffer  for  5  minutes.Four  pieces  of  pre-cut  whatman  paper,  which  have  been  soaked  in  
the  continuous  transfer  buffer,  were  placed  on  the  anode  electrode  plate.  The  equilibrated  
membrane  was  transferred  to  the  whatman  paper;  taking  care  to  avoid  any  air  bubbles  from  
being  formed  between  any  of  the  layers.  To  help  prevent  the  formation  of  air  bubbles  between  
the  membrane  and  the  gel  layered  just  above  it,  a  small  amount  of  continuous  transfer  buffer  
was  gently  poured  on  the  membrane  before  the  gel  was  placed  on  top.  An  additional  4  pieces  of  
whatman  paper,  soaked  in  the  continuous  transfer  buffer,  were  placed  on  top  of  the  gel.  Any  
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excess  transfer  buffer  was  wiped  off  of  the  anode  plate  and  the  cathode  plate  was  then  placed  
on  top  and  the  transfer  proceeded  at  250mA  for  40  minutes.   
After  the  transfer,  non-specific  protein-protein  interactions  were  blocked  by  incubating  
the  membrane  under  constant  agitation  in  5%  milk,  diluted  in  TBST  buffer  (see  recipe  in  
Appendix),  overnight  at  room  temperature.  After  blocking,  the  membrane  was  washed  5  times  at  
5  minutes  per  wash  with  TBST  and  then  incubated  with  the  primary  antibody  (according  to  the  
previously  mentioned  dilutions)  under  constant  agitation  for  4  hours,  at  room  temperature.  The  
membrane  is  washed  again  with  TBST  (5  washes  at  5  minutes  per  wash),  and  then  incubated 
under  constant  agitation  for  1  hour,  at  room  temperature,  with  the  secondary  antibody.  The  
membrane  was  thoroughly  washed  multiple  times  with  TBST  before  proteins  are  visualized  
through  chemiluminescence.  
To  visualize  the  proteins  from  the  Western  blot,  chemiluminescence  using  Millipore 
substrate  was  performed.  Chemiluminescent  substrates  for  the  horseradish  peroxidase  (HRP)  
are  a  two-component  system,  consisting  of  a  stable  peroxide  solution  and  an  enhanced  luminol 
solution.  To  make  a  working  solution  of  substrate,  equal  volumes  of  the  two  components  
(Millipore)  were  mixed  together.  The  chemiluminescent  working  substrate  was  incubated  on  the  
membrane  for  3  minutes,  at  room  temperature.  Excess  substrate  was  removed  from  the  
membrane  before  exposure.  A  BioRad  Universal  Hood  II  light  box  with  a  Quantity  One  program  
was  used  to  visualize  proteins  recognized  by  the  primary  antibody.   
Cell  Culture  Transcription  Inhibition  
  Actinomycin  D  (0.5  mg/ml)  was  used  to  treat  HT29  cells  to  inhibit  transcriptional  activity.  
Cells  were  seeded  at  a  density  of  8x10 5   on  18mm 2   coverslips  and  allowed  to  adhere  overnight  
in  normal,  complete  DMEM/F12  media.  The  following  day  the  normal  media  was  removed  and  
51  
cells  were  treated  with  complete  DMEM/F12  media  with  Actinomycin  D  at  a  1:1000  dilution.  
Control  cells  were  incubated  with  70%  ethanol.  Cells  were  left  in  the  treatment  media  for  2,  4,  
and  8  hours  before  they  were  fixed  and  visualized  following  the  protocol  in  the  
Immunocytochemistry  section.   
Cell  Cycle  Synchronization  
  HT29  cells  were  synchronized  using  Staurosporine  (0.5  mg/ml;  Millipore,  569397),  
Aphidicolin  (10  mg/ml;  Millipore,  178273),  and  Temozolomide  (20  mg/ml;  Sigma,  T2577),  which  
block  the  cell  cycles  in  the  G1  phase,  S  phase,  and  G2-M  phase,  respectively.  To  synchronize  
cells,  8x10 5  cells  were  seeded  on  18  mm 2  coverslips  in  normal,  complete  DMEM/F12  media  and  
allowed  to  adhere  overnight.  The  media  was  removed  and  replaced  with  complete  DMEM/F12  
media  containing  the  specific  inhibitor  at  a  1:1000  dilution.  Cells  were  kept  in  treatment  media  
for  24  and  36  hours.  Control  coverslips  were  treated  with  DMSO.  The  coverslips  were  used  for  
immunocytochemistry  to  visualize  cell  cycle  specific  localization  of  isoform  B/myopodin.   
Immunocytochemistry  
Immunocytochemistry  was  used  to  localize  isoform  B/myopodin  within  the  cell  
structures.  An  asynchronous  cell  population,  as  well  as  cells  blocked  in  specific  phases  of  the  
cell  cycle,  were  used  to  visualize  protein  localization  within  the  cells.  Cells  were  seeded  on  
coverslips  and  allowed  to  adhere  overnight.  Cells  were  cultured  to  approximately  50%  -  75%  
confluency.  To  fix  cells  on  coverslips,  the  media  was  first  removed  and  the  coverslips  were  
washed  twice  with  PBS/Mg 2+ ,  Ca 2+ .  Cells  were  fixed  with  3.7%  formalin  in  PBS/Mg 2+ ,  Ca 2+   for  8  
minutes  at  room  temperature.  Cells  were  permeated  with  0.1%  Triton-X100  in  1X  PBS  at  room  
temperature  for  4  minutes.  After  a  short  rinse  with  1X  PBS,  unspecific  protein-protein  
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interactions  were  blocked  with  10%  FBS  in  1X  PBS  for  45  minutes,  at  room  temperature.  The  
blocking  solution  was  then  removed  and  cells  were  incubated  with  the  primary  antibodies,  
diluted  in  10%  FBS/PBS,  and  incubated  for  45  minutes.  The  coverslips  were  washed  with  1X  
PBS  3  times  for  10  minutes  per  wash  and  the  cells  were  then  incubated  with  the  appropriate  
secondary  antibody.  Since  the  secondary  antibodies  are  conjugated  with  a  fluorescence  dye,  
the  coverslips  were  kept  in  the  dark  while  incubating  for  an  additional  45  minutes,  at  room  
temperature.  The  coverslips  were  kept  in  the  dark  to  preserve  their  fluorescence  for  optimal  
visualization.  After  the  final  wash  in  1X  PBS  the  coverslips  are  mounted  with  Vectashield  (Vector  
Laboratories,  Inc.)  and  observed  using  an  Olympus  BX40  microscope.  A  QColor  5  Olympus  
camera  and  the  QCapture  Pro  6.0  program  were  used  to  generate  cell  pictures.  
The  NC_781  antibody  was  tittered  out  and  a  1:600  dilution  was  established  as  the  
optimal  working  dilution.  The  synaptopodin-2  non-isoform  specific  Pan  antibody  (ab50192)  and  
zyxin  (ab58210)  were  purchased  from  abcam.  The  β-actin  antibody  (A1978)  was  purchased  
from  Sigma,  as  well  as  the  goat  anti-rabbit  (IgG,  F(ab) 2   fragment-FITC)  and  the  sheep  
anti-mouse  (IgG,  F(ab) 2   fragment-Cy3)  secondary  antibodies.   A  mouse  anti-Nucleolin  
(39-6400)  antibody  was  purchased  from  invitrogen.  Purchased  antibodies  were  used  at  the  
manufactures  determined  working  concentration.  
Antigen  Competition  Assay  
To  ensure  that  the  expression  pattern  obtained  through  immunocytochemistry  was  the  
result  NC_781  recognizing  its  appropriate  epitope  and  not  an  artifact,  a  binding  competition  
assay  was  performed.  To  do  this,  the  minimal  amount  of  antibody  required  to  detect  a  
fluorescence  signal  was  first  determined.  A  1:1,200  dilution  of  the  stock  NC_781  antibody  was  
the  lowest  concentration  that  yielded  a  detectable  signal  through  immunofluorescence.  
Therefore  a  1:1,200  was  the  final  dilution  factor  used  for  the  antibody.  The  NC_781  antibody  
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was  incubated  with  the  antigen  amino  acid  sequence  that  processed  the  epitope  
(VWKPSVVEE)  at  different  molar  concentration  ratios  (antibody:antigen;  1:188,  1:150,  1:125)  at  
room  temperature  for  4  hours  under  gentle  but  constant  agitation.  After  the  incubation,  samples  
were  centrifuged  at  10,000  rpm  at  4ᴼC  for  30  minutes.  The  upper  portion  of  the  supernatant  was  
collected  and  used  as  the  primary  antibody  for  immunocytochemistry.  As  a  control,  BSA  was  
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APPENDIX   
Appendix  A:  Tables  
Table  1:   Primer  Sequences  for  individual  Synaptopodin-2  Isoforms  
  
Table  1:  RT-PCR  primer  sequences  for  the  individual  synaptopodin-2  isoforms.  The 
appropriate  annealing  temperatures  and  product  lengths  for  the  individual  isoforms  are  
indicated.  
  
Table  2:  Primer  Sequences  for  Isoform  B  and  Myopodin  Full-Length  Gene   
      PCR  Amplification   
Table  2:  Primer  sequences  for  full  length  gene  amplification  of  synaptopodin-2  Isoform  B  
and  myopodin.  The  appropriate  annealing  temperature  and  expected  product  length  is  
indicated.  
  




Synpo2  variant  1F  ATCAGCCTCATCATCTTATTTTGT   59  °C  251  bp  
Synpo2  variant  1R    CCACTAGACCGAGAGGAGACTTTG   
Synpo2  variant  2F    AAAGCAAGAATCAGCCTCATCATC   66  °C  192  bp  
Synpo2  variant  2R    GCTAGGCATTCTCAGGGACTCAAG   
Synpo2  variant  3F    TCCCACCTCGCCAAAGCAAGAAT   59  °C  252  bp  
Synpo2  variant  3R    GGAGCCCAAGAAATAGGAGATGTG   




Synpo2StartF  GAGAAGCTTAAAACATGGGCACAGGGGATTTT 
ATCTGC   








CCCCTCCCTCTTCCACAACAGATGGTTTCC  60°C  3282  bp  
  
  
Table  3:  SDS-Gel  Recipe   
Table  7:  Recipe  for  making  different  concentrations  of  SDS-polyacrylamide  gels.  
Bis-acrylamide  was  purchased  through  BioRad.  Resolving  *Gel  Buffer-  1.5M  Tris-HCl,  pH  
8.8;  *Stacking  Gel  Buffer-  0.5M  Tris-HCl,  pH  6.8.  For  resolving  gels  add  50  µl  10%  APS  























DDI  H2O  
(ml)  
40%  Degassed  
Acrylamide/Bis   (ml)  
Gel  Buffer*  
(ml)  
10%  (w/v)  SDS  
(ml)  
4%  6.4  1  2.5  0.1  
6%  5.9  1.5  2.5  0.1  
  
Appendix  B-  Recipes  
● 10  %  (w/v)  SDS  
o 10  g  of  SDS  in  90  ml  of  water.  Stir  gently  and  bring  the  total  volume  to  100  ml  
with  double  distilled  water.  
  
● 1.5  M  Tris-HCl,  pH  8.8  
o 27.23  g  of  Tris  base  (18.15  g/100  ml)  and  add  80  ml  of  double  distilled  water.  
Adjust  pH  to  8.8  with  6N  HCl.  Bring  total  volume  to  150  ml  with  double  distilled  
water  and  store  at  4ᵒC.   
  
● 0.5  M  Tris-HCl,  pH  6.8  
o 6  g  Tris  base  and  add  60  ml  of  double  distilled  water.  Adjust  pH  with  6N  HCl  and  
bring  total  volume  to  100  ml  with  double  distilled  water.  Store  at  4ᵒC.  
  
● 10X  Electrode  (Running)  Buffer,  pH  8.3  
o 30.3  g  Tris  base  
o 144.0  g  glycine  
o 10.0  g  SDS  
o Dissolve  and  bring  the  total  volume  to  1,000  ml  with  double  distilled  water.  The  
buffer  solution  was  stored  at  4ᵒC.  If  precipitation  occurred,  the  buffer  was  
warmed  to  room  temperature  before  use.   
  
● 10  %  (w/v)  APS   
o Dissolve  100  mg  of  ammonium  persulfate  in  1  ml  of  double  distilled  water.  Store  
at  4ᵒC  up  to  one  week.  
  
● 50X  TAE  Stock  Solution  (For  preparing  and  running  PCR  gels)  
o 242g  Tris  Base  (MW=  121.1g/mol),  57.1  ml  Glacial  Acetic  Acid,  100  ml  0.5M  
EDTA.  Bring  to  the  final  volume  of  1  L  with  ddH 2 O.  
  
● Continuous  Transfer  Buffer  
o 2.93g  Glycine  
o 5.82g  Tris  base  
o 0.0375g  SDS  
o 200ml  Methanol  
o Dissolve  and  bring  the  total  volume  to  1,000  ml  with  double  distilled  water.  The  
buffer  solution  was  stored  at  4ᵒC.   
  
● Tris-buffered  Saline  (TBS)  10X  
o 24.23  g  Trizma  HCl  
o 80.06  g  NaCl  
o pH  to  7.6  with  pure  HCl  





● Tris-buffered  saline  with  Tween20  (TBST)  1X  
o 100ml  TBS  10X  
o 900ml  double  distilled  water  
o 1ml  Tween20  
  
● Phosphate-buffered  Saline  (PBS)  10X  
o NaCl  80g  
o KCl  2g  
o KH2PO4  2g  
o Na2HPO4   11.3g  
o Dissolve  and  bring  the  total  volume  to  1,000  ml  with  double  distilled  water.   
  
● PBS/Mg 2+,   Ca 2+   1X  
o 5  ml  of  100  mM  MgCl2  
o 9  ml  of  100  mM  CaCl2  
o 100  ml  of  10X  PBS  
o Dissolve  and  bring  the  total  volume  to  1,000  ml  with  double  distilled  water.   
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